# ðŸ“„ Template: Pharma

## Business Description

IndSwift Ltd is a leading Indian pharmaceutical company specializing in the development, manufacturing, and marketing of a wide range of pharmaceutical products, including Active Pharmaceutical Ingredients (APIs) and herbal products. The company operates multiple divisions, such as Noble, Nova, Ethical, and Generic, and has established a strong presence in both domestic and international markets, exporting to 45 countries. With ISO 9001:2008 and WHO GMP certifications, IndSwift is recognized for its commitment to quality and safety, ranking 35th in the Indian pharma industry and being the second largest manufacturer in North India.

## Website
https://www.indswiftlabs.com/

## Product & Services

- **Noble Division**  
- **Nova Division**  
- **Ethical Division**  
- **Generic Division**  
- **Institution Division**  
- **Global Business Unit**  
- **Formulation Division**  

## Product Portfolio

| DRUG / MEDICINE | ACTIVE INGREDIENT | THERAPEUTIC CLASS | THERAPEUTIC SUBCLASS | ATC CODE | CLASS | USAGE |
|---|---|---|---|---|---|---|
| Indlith | Lithium carbonate | Central Nervous System | Antipsychotics | N05AN01 | Lithium Antipsychotics | - |
| Zocin Inj | Pentazocine | Central Nervous System | Analgesics (Opioid) | N02AD01 | Benzomorphan Derivative Opioids | Relieve Pain |
| Amibex-NA | Metronidazole, Nalidixic acid | Anti-Infectives (Systemic) | Other Antibiotics | J01RA | - | Systemic Treatment of Infections |
| Agile | Diclofenac Na, Paracetamol | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB05 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Adams Delite | Sildenafil citrate | Genito-Urinary System | Drugs for Erectile Dysfunction & Ejaculatory Disorders | G04BE03 | Drugs Used in Erectile Dysfunction | - |
| Agile-MR | Chlorzoxazone, Diclofenac Na, Paracetamol | Musculo-Skeletal System | Muscle Relaxants | M01AB05 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Alltop-P | Alprazolam, Propranolol HCl | Cardiovascular & Hematopoietic System | Beta-Blockers | C07AA05 | Non-selective Beta-blocking Agents | Treatment of Cardiovascular Diseases |
| Amyclox | Amoxicillin, Cloxacillin | Anti-Infectives (Systemic) | Penicillins | J01CR50 | Penicillin Combinations, Including Beta-lactamase Inhibitors | Systemic Treatment of Infections |
| Agile T-Gel | Diclofenac diethylammonium, Menthol, Methyl salicylate, Oleoresin capsicum, Oleum lini | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB55 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Alfexo | Fexofenadine | Allergy & Immune System | Antihistamines & Antiallergics | R06AX26 | other Antihistamines for Systemic Use | - |
| Ambicet | Ambroxol, Levocetirizine | Respiratory System | Cough & Cold Preparations | R05CB10 | Mucolytics | Treatment of Wet Cough |
| Angitol Plus | Amlodipine, Atenolol | Cardiovascular & Hematopoietic System | Beta-Blockers | C07FB | - | Treatment of Cardiovascular Diseases |
| Becmet-CG Crm | Beclometasone dipropionate, Clotrimazole, Gentamicin sulphate | Dermatological Therapy | Topical Antifungals & Antiparasites | D01AC20 | Imidazole and Triazole Derivatives | Topical Treatment of Fungal Infection |
| Acsolve-C | Clindamycin, Tretinoin | Dermatological Therapy | Acne Treatment Preparations | D10AD51 | Topical Retinoid Preparations | Treatment of Acne |
| Aniwel | Caraway oil, Cardamom oil /mL, Cinnamon oil, Fungal diastase | Gastrointestinal & Hepatobiliary System | Digestives | A09AA | - | Digestives |
| Alice-D | Domperidone, Paracetamol | Central Nervous System | Antimigraine Preparations | N02BE51 | Anilide Preparations | Relieve Pain and Fever |
| Artica | Glucosamine sulfate | Health Supplements & Food | Supplements & Adjuvant Therapy | M01AX05 | other Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Barbee | Phenobarbital | Central Nervous System | Anticonvulsants | N03AA02 | Barbiturates and Derivatives Antiepileptics | - |
| Becmet-S | Beclometasone dipropionate, Salicylic acid | Dermatological Therapy | Topical Corticosteroids | D07XC | - | Treatment of Dermatological Diseases |
| Anin | Allyloestrenol | Hormones | Oestrogens, Progesterones & Related Synthetic Drugs | G03DC01 | Estren Derivative Progestogens Used in Progestogenic Hormone Preparations | - |
| Anaproct Oint | Allantoin, Hydrocortisone acetate, Lidocaine, Zn oxide | Gastrointestinal & Hepatobiliary System | Anorectal Preparations | C05AX | - | Topical Treatment of Hemorrhoids and Anal Fissures |
| Arthrill | Allium sativum, Anthocephalus cadamba, Camphor, Capsaicin, Cedrus deodara, Commiphora mukul, Eucalyptus oil 2.5 % v/v/, Menthol, Paederia foetida, Pluchea indica, Prunus amygdalus, Ricinus communis, Strychnos nux-vomica, Trachyspermum ammi, Vitex negundo, Wintergreen oil 25 % v/v, Withania somnifera | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AX | - | Treatment of Inflammation and Rheumatism |
| Cetin Plus | Cetirizine diHCl, Paracetamol, Pseudoephedrine HCl | Allergy & Immune System | Antihistamines & Antiallergics | R01BA52 | Systemic Sympathomimetic Preparations Used as Nasal Decongestants | - |
| Cefzid | Ceftazidime | Anti-Infectives (Systemic) | Cephalosporins | J01DD02 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Brain Rest | Haloperidol | Central Nervous System | Antipsychotics | N05AD01 | Butyrophenone Derivatives Antipsychotics | - |
| Becmet-GM | Beclometasone dipropionate, Gentamicin, Miconazole nitrate | Dermatological Therapy | Topical Corticosteroids | D07CC04 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Anacid | Al(OH) 3 gel, dried, Mg(OH) 2, Simeticone | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02AF | - | Treatment of Acid-related Disorders |
| Amtop | Amikacin | Anti-Infectives (Systemic) | Aminoglycosides | J01GB06 | other Aminoglycosides | Systemic Treatment of Infections |
| Emef | Moxifloxacin HCl | Eye | Eye Anti-Infectives & Antiseptics | S01AE07 | Quinolone Antiinfectives | Treatment of Eye Infections |
| Cazol | Clotrimazole | Dermatological Therapy | Topical Antifungals & Antiparasites | D01AC01 | Imidazole and Triazole Derivatives | Topical Treatment of Fungal Infection |
| Cancap-VT | Clotrimazole | Genito-Urinary System | Preparations for Vaginal Conditions | G01AF02 | Imidazole Derivative Antiinfectives | Treatment of Gynecological Infections |
| Calskin | Alcohol 2.37 % v/v, Calamine, Camphor, Diphenhydramine | Dermatological Therapy | Topical Antihistamines/Antipruritics | D04AX | - | Treatment of Pruritus |
| Dabby | Gliclazide, Metformin HCl | Hormones | Antidiabetic Agents | A10BD02 | Combinations of Oral Blood Glucose Lowering Drugs | Treatment of Diabetes |
| Clarie-OD | Clarithromycin | Anti-Infectives (Systemic) | Macrolides | J01FA09 | Macrolides | Systemic Treatment of Infections |
| Cozy-AM Tab | Ambroxol HCl, Guaiphenesin, Loratadine | Respiratory System | Cough & Cold Preparations | R05CA10 | Expectorants | Treatment of Wet Cough |
| Cozy Cool | Chlorpheniramine maleate, Phenylephrine | Respiratory System | Cough & Cold Preparations | R01BA53 | Systemic Sympathomimetic Preparations Used as Nasal Decongestants | - |
| Deprox | Paroxetine | Central Nervous System | Antidepressants | N06AB05 | Selective Serotonin Reuptake Inhibitors | Management of Depression |
| Atstat | Atorvastatin | Cardiovascular & Hematopoietic System | Dyslipidaemic Agents | C10AA05 | Hmg Coa Reductase Inhibitors | Treatment of Hyperlipidemia |
| CNB | Beclometasone dipropionate, Clotrimazole, Neomycin | Dermatological Therapy | Topical Corticosteroids | D07CC04 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Aztec | Ranitidine | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BA02 | H2-receptor Antagonists | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Dicol Plus | Diclofenac Na, Paracetamol | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB05 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Cancap | Fluconazole | Anti-Infectives (Systemic) | Antifungals | J02AC01 | Triazole and Tetrazole Derivatives | Systemic Treatment of Mycotic Infections |
| Cordimil | Ramipril | Cardiovascular & Hematopoietic System | ACE Inhibitors/Direct Renin Inhibitors | C09AA05 | Ace Inhibitors | Treatment of Cardiovascular Disease |
| Clobequad | Beclomethasone dipropionate, Gentamicin sulphate, Iodochlorhydroxyquinoline, Miconazole nitrate | Dermatological Therapy | Topical Anti-Infectives with Corticosteroids | D07CC04 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Cincillin | Ampicillin | Anti-Infectives (Systemic) | Penicillins | J01CA01 | Penicillins with Extended Spectrum | Systemic Treatment of Infections |
| Diaze | Diazepam | Central Nervous System | Anxiolytics | N05BA01 | Benzodiazepine Derivatives Anxiolytics | Management of Anxiety, Agitation or Tension |
| Caplor | Clopidogrel | Cardiovascular & Hematopoietic System | Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics) | B01AC04 | Platelet Aggregation Inhibitors Excluding Heparin | Treatment of Thrombosis |
| Calswift | Ca gluconate, Cyanocobalamin, Vit D3 | Vitamins & Minerals | Calcium/with Vitamins | A12AX | - | Dietary Supplements |
| Dicoliv Plus | Diclofenac Na, Paracetamol | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB05 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Dicol-MR | Chlorzoxazone, Diclofenac K, Paracetamol | Musculo-Skeletal System | Muscle Relaxants | M03BB53 | Oxazol, Thiazine, and Triazine Derivative Agents | Centrally-acting Muscle Relaxants |
| Faxtin | Fluoxetine | Central Nervous System | Antidepressants | N06AB03 | Selective Serotonin Reuptake Inhibitors | Management of Depression |
| Delin | Etofylline, Theophylline | Respiratory System | Antiasthmatic & COPD Preparations | R03DA54 | Xanthines | Systemic Treatment of Obstructive Airway Diseases |
| Dicol | Diclofenac | Eye | Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories | S01BC03 | Non-steroidal Antiinflammatory Agents | Treatment of Inflammation of the Eye |
| Eelovit | Aloe vera, Vit E | Dermatological & Personal Care | Emollients, Cleansers & Skin Protectives | D02AX | - | Skin Emollients and Protectants |
| Cefasul | Per 500/ Pwd-Inj Cefoperazone Na, Sulbactam Na, Sulbactam Na . Per 1/ Pwd-Inj Cefoperazone Na | Anti-Infectives (Systemic) | Cephalosporins | J01DD62 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Dilcare | Atenolol | Cardiovascular & Hematopoietic System | Beta-Blockers | C07AB03 | Selective Beta-blocking Agents | Treatment of Cardiovascular Diseases |
| Evitop-C | Cod liver oil, Vit E acetate | Vitamins & Minerals | Vitamins A, D & E | V06DX | - | General Nutrients |
| Elucin | Erythromycin | Anti-Infectives (Systemic) | Macrolides | J01FA01 | Macrolides | Systemic Treatment of Infections |
| D-Lordex | Desloratadine | Allergy & Immune System | Antihistamines & Antiallergics | R06AX27 | other Antihistamines for Systemic Use | - |
| Dilpril | Enalapril | Cardiovascular & Hematopoietic System | ACE Inhibitors/Direct Renin Inhibitors | C09AA02 | Ace Inhibitors | Treatment of Cardiovascular Disease |
| Dicoliv-MR | Chlorzoxazone, Diclofenac K, Paracetamol | Musculo-Skeletal System | Muscle Relaxants | M03BB53 | Oxazol, Thiazine, and Triazine Derivative Agents | Centrally-acting Muscle Relaxants |
| Etoxin-B Exp | Bromhexine HCl, Guaiphenesin, Menthol, Terbutaline sulphate | Respiratory System | Antiasthmatic & COPD Preparations | R03CC53 | Adrenergics for Systemic Use, Selective Beta-2-adrenoreceptor Agonists | Treatment of Obstructive Airway Diseases |
| E-coff | Ammon Cl, Chlorphenamine maleate, Na | Respiratory System | Cough & Cold Preparations | R05CA10 | Expectorants | Treatment of Wet Cough |
| Fencol | Chloramphenicol | Anti-Infectives (Systemic) | Chloramphenicols | J01BA01 | Amphenicols | Systemic Treatment of Infections |
| Ferritop Paed Syr | Cyanocobalamin, Fe ammon citrate, Folic acid | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE01 | Iron in other Combinations | Treatment of Anemia |
| Cini | Cinnarizine | Central Nervous System | Antivertigo Drugs | N07CA02 | Antivertigo Preparations | - |
| Ferritop Iron | Cyanocobalamin, Fe ammon citrate, Folic acid /mL, Lysine HCl | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE | - | Treatment of Anemia |
| Cozy Plus | Anhydrous caffeine, Chlorpheniramine maleate, Paracetamol, Phenylephrine HCl | Respiratory System | Cough & Cold Preparations | R01BA53 | Systemic Sympathomimetic Preparations Used as Nasal Decongestants | - |
| Erase | Erythromycin stearate | Anti-Infectives (Systemic) | Macrolides | J01FA01 | Macrolides | Systemic Treatment of Infections |
| Expodox | Cefpodoxime proxetil | Anti-Infectives (Systemic) | Cephalosporins | J01DD13 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Feritin Tab | Ferric polymaltose, Folic acid | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AD | - | Treatment of Anemia |
| Domtop | Domperidone | Gastrointestinal & Hepatobiliary System | Antiemetics | A03FA03 | Propulsives | Treatment of Functional Gastrointestinal Disorders |
| Ergest-LD | Ethinyl estradiol, Levonorgestrel | Hormones | Oestrogens, Progesterones & Related Synthetic Drugs | G03AA07 | Progestogens and Estrogens in Fixed Combinations | Systemic Contraceptives |
| Garlee | Garlic | Cardiovascular & Hematopoietic System | Dyslipidaemic Agents | C10AX | - | Treatment of Hyperlipidemia |
| Glucose-D | Ca, Dextrose monohydrate, Phosphorus, Vit D / | Nutrition | Electrolytes | A07CA | - | Treatment of Diarrhea |
| Glitter | Pioglitazone | Hormones | Antidiabetic Agents | A10BG03 | Thiazolidinediones | Treatment of Diabetes |
| Hem Forte | Folic acid, Folic acid . Syr Fe (III) hydroxide polymaltose complex, O-Dps Fe (III) hydroxide polymaltose complex | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AD | - | Treatment of Anemia |
| Gutts | Gatifloxacin | Eye | Eye Anti-Infectives & Antiseptics | S01AE06 | Quinolone Antiinfectives | Treatment of Eye Infections |
| Hycort | Hydrocortisone Na succinate | Hormones | Corticosteroid Hormones | H02AB09 | Glucocorticoids | Systemic Corticosteroid Preparations |
| Indaxin-B6 | Doxylamine succinate, Pyridoxine HCl | Allergy & Immune System | Antihistamines & Antiallergics | R06AA59 | Aminoalkyl Ethers Used as Systemic Antihistamines | - |
| Fru | Furosemide | Cardiovascular & Hematopoietic System | Diuretics | C03CA01 | High-ceiling Sulfonamide Diuretics | - |
| Hyoswift | Hyoscine butylbromide | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03BA03 | Belladonna Alkaloids, Tertiary Amines | Treatment of Functional Gastrointestinal Disorders |
| Indcel | Clavulanate K, Per Tab Amoxicillin | Anti-Infectives (Systemic) | Penicillins | J01CR02 | Penicillin Combinations, Including Beta-lactamase Inhibitors | Systemic Treatment of Infections |
| Fertilin | Clomifene | Hormones | Trophic Hormones & Related Synthetic Drugs | G03GB02 | Synthetic Agents Used as Ovulation Stimulants | - |
| Ketoco | Ketoconazole | Dermatological Therapy | Psoriasis, Seborrhea & Ichthyosis Preparations | D01AC08 | Imidazole and Triazole Derivatives | Topical Treatment of Fungal Infection |
| Fucin-B | Beclometasone dipropionate, Fusidic acid | Dermatological Therapy | Topical Antibiotics | D07CC04 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Inorine-M | Drotaverine, Mefenamic acid | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03DC | - | Treatment of Functional Gastrointestinal Disorders |
| Link | Lincomycin HCl | Anti-Infectives (Systemic) | Other Antibiotics | J01FF02 | Lincosamides | Systemic Treatment of Infections |
| Lorphen | Flurbiprofen sodium | Eye | Other Eye Preparations | S01BC04 | Non-steroidal Antiinflammatory Agents | Treatment of Inflammation of the Eye |
| Indox | Oxytocin | Genito-Urinary System | Drugs Acting on the Uterus | H01BB02 | Oxytocin and Analogues | Posterior Pituitary Lobe Hormone Preparations |
| Menoguard | Ethamsylate, Tranexamic acid | Cardiovascular & Hematopoietic System | Haemostatics | B02BX | - | Treatment of Hemorrhage |
| Lycomax | Lycopene 10%, Selenium dioxide, Vit A acetate, Vit C, Zn sulphate monohydrate | Vitamins & Minerals | Vitamins &/or Minerals | V06DX | - | General Nutrients |
| Methin | Methylergometrine maleate | Genito-Urinary System | Drugs Acting on the Uterus | G02AB01 | Ergot Alkaloids | Induce Abortion or Augment Labour and to Minimize Blood Loss from the Placental Site |
| Merigel-A | Magaldrate, Oxetacaine, Simethicone | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02AX | - | Treatment of Acid-related Disorders |
| Metoclop-P | Metoclopramide HCl, Paracetamol | Central Nervous System | Antimigraine Preparations | N02BE51 | Anilide Preparations | Relieve Pain and Fever |
| Liza-D | Domperidone, Lansoprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BC53 | Proton Pump Inhibitors | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Nelsid | Nimesulide | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AX17 | other Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Mictop-F | Fluocinolone acetonide, Miconazole nitrate | Dermatological Therapy | Topical Antifungals & Antiparasites | D01AE | - | Topical Treatment of Fungal Infection |
| Lospot-AM | Amlodipine, Losartan K | Cardiovascular & Hematopoietic System | Other Antihypertensives | C09DB06 | Angiotensin Ii Receptor Blockers (arbs) and Calcium Channel Blockers | Treatment of Cardiovascular Disease |
| Nelsid-D | Dicyclomine HCl, Nimesulide | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03DC | - | Treatment of Functional Gastrointestinal Disorders |
| Nelsid Plus | Nimesulide, Paracetamol | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AX | - | Treatment of Inflammation and Rheumatism |
| Jovin | Hypericum perforatum extr | Central Nervous System | Antidepressants | N06AX | - | Management of Depression |
| Genta Swift E/E-Dps | Gentamycin | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S03AA06 | Antiinfectives Used in Ophthalmologic and Otologic Preparations | - |
| MU-Oint | Mupirocin | Dermatological Therapy | Topical Antibiotics | D06AX09 | other Topical Antibiotics Used in the Treatment of Dermatological Diseases | - |
| L-Oxo | Levofloxacin | Anti-Infectives (Systemic) | Quinolones | J01MA12 | Fluoroquinolones | Systemic Treatment of Infections |
| Listn | K nitrate, Na monochlorophosphate | Ear & Mouth / Throat | Preparations for Oral Ulceration & Inflammation | A01AA | - | the Prevention of Dental Cavities |
| Malther | Î±/Î²-arteether | Anti-Infectives (Systemic) | Antimalarials | P01BE04 | Artemisinin and Derivative Antimalarials | - |
| Floxil-O | Ofloxacin | Eye | Eye Anti-Infectives & Antiseptics | S02AA16 | Antiinfectives Used in the Treatment of Ear Infections | - |
| Ferritop-Z | Carbonyl Fe, Folic acid, Selenium, Vit B12, Vit C, Vit E, Zn sulphate | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE | - | Treatment of Anemia |
| Neotop | Neomycin sulphate, Sulphacetamide, Zn bacitracin | Dermatological Therapy | Topical Antibiotics | D06AX | - | Treatment of Dermatological Diseases |
| Livasa Syr | Achillea millefolium, Andrographis paniculata, Boerhaavia diffusa, Cichorium intybus, Eclipta alba, Fumaria parviflora, Milk thistle, Phyllanthus emblica, Phyllanthus niruri, Picrorhiza kurroa, Piper nigrum, Rhubarb, Solanum nigrum, Terminalia chebula, Vitis vinifera | Gastrointestinal & Hepatobiliary System | Cholagogues, Cholelitholytics & Hepatic Protectors | A05C | - | Bile and Liver Therapy |
| Gdsafe-DS | Colistin sulphate | Anti-Infectives (Systemic) | Other Antibiotics | A07AA10 | Antibiotics | Treatment of Intestinal Infections |
| Neurobex Syr | D-Panthenol, L-Lysine monohydrochloride, Vit B1, Vit B12, Vit B2, Vit B6 | Nutrition | Enteral/Nutritional Products | A11JC | - | Dietary Supplements |
| Neurobex-Z | Ca pantothenate, Lactobacillus 60 million cells, Nicotinamide, Vit A acetate, Vit B 1 mononitrate, Vit B12, Vit B2, Vit B6, Vit C | Vitamins & Minerals | Vitamins &/or Minerals | A11JC | - | Dietary Supplements |
| Neurophen Tab | Chlorpheniramine maleate, Diclofenac Na, Mg trisilicate, Paracetamol | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB55 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Neurobex Inj | D-Panthenol, Nicotinamide, Vit B1, Vit B12, Vit B6 | Vitamins & Minerals | Vitamin B-Complex / with C | A11EA | - | Dietary Supplements |
| Oracalcid-B12 | Ca phosphate, Vit B12, Vit D3 | Vitamins & Minerals | Calcium/with Vitamins | A11JB | - | Dietary Supplements |
| Neurospas-MF | Dicyclomine HCl, Mefenamic acid | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03ED | - | Treatment of Functional Gastrointestinal Disorders |
| Ozo | Omeprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BC01 | Proton Pump Inhibitors | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Norrit-ORD | Norfloxacin, Ornidazole | Gastrointestinal & Hepatobiliary System | Antidiarrheals | J01RA | - | Systemic Treatment of Infections |
| Oxo-TZ | Ofloxacin, Tinidazole | Anti-Infectives (Systemic) | Quinolones | J01RA18 | Combinations of Antibacterials | Systemic Treatment of Infections |
| Netazox-OF | Ofloxacin, Ofloxacin . O-Susp Nitazoxanide, Tab Nitazoxanide | Anti-Infectives (Systemic) | Quinolones | P01AX | - | Treatment Amoebiasis and other Protozoal Diseases |
| Neurospas Dps | activated Dimeticone, Dicyclomine HCl | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03ED | - | Treatment of Functional Gastrointestinal Disorders |
| Ovidine-M | Crm Povidone iodine, Metronidazole, Metronidazole . T-Pwd Povidone iodine | Dermatological Therapy | Topical Antibiotics | D06BX01 | other Topical Chemotherapeutics Used in the Treatment of Dermatological Diseases | - |
| Nelsid-S | Nimesulide, Serratiopeptidase (EC) | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01BX | - | Treatment of Inflammation and Rheumatism |
| P-Chlor | KCl | Nutrition | Electrolytes | A12BA01 | Potassium-containing Preparations | Dietary Supplements |
| Malquine | Primaquine phosphate | Anti-Infectives (Systemic) | Antimalarials | P01BA03 | Aminoquinoline Antimalarials | - |
| Pentagon-D | Domperidone, Pantoprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BC02 | Proton Pump Inhibitors | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Oxo-M | Metronidazole benzoate, Ofloxacin | Anti-Infectives (Systemic) | Quinolones | J01RA | - | Systemic Treatment of Infections |
| Neurophen Compound | Diclofenac Na, Nimesulide | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01BX | - | Treatment of Inflammation and Rheumatism |
| Nozy Cold | Nimesulide, Pseudoephedrine | Respiratory System | Cough & Cold Preparations | R01BA52 | Systemic Sympathomimetic Preparations Used as Nasal Decongestants | - |
| Primecet | Levocetirizine diHCl | Allergy & Immune System | Antihistamines & Antiallergics | R06AE09 | Piperazine Derivatives Used as Systemic Antihistamines | - |
| Norrit | Norfloxacin | Eye | Eye Anti-Infectives & Antiseptics | S01AE02 | Quinolone Antiinfectives | Treatment of Eye Infections |
| Pentazen Inj | Tramadol HCl | Central Nervous System | Analgesics (Opioid) | N02AX02 | other Opioids | Relieve Pain |
| Ovidine | Povidone iodine | Dermatological Therapy | Skin Antiseptics & Disinfectants | D08AG02 | Iodine Product Antiseptics | Treatment of Dermatological Diseases |
| Predyl | Prednisolone acetate | Eye | Eye Corticosteroids | S01BA04 | Corticosteroids | Treatment of Inflammation of the Eye |
| Stedex Inj | Dexamethasone | Hormones | Corticosteroid Hormones | H02AB02 | Glucocorticoids | Systemic Corticosteroid Preparations |
| Pulse-BD | Chloramphenicol, Dexamethasone, Polymyxin B | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S03CA01 | Combinations of Corticosteroids and Antiinfectives Used in Ophthalmologic and Otologic Preparations | - |
| Stemin-MF | Betamethasone dipropionate, Lactic acid, Salicylic acid, Urea | Dermatological Therapy | Psoriasis, Seborrhea & Ichthyosis Preparations | D07XC01 | Potent (group Iii) Corticosteroids in other Combinations | Treatment of Dermatological Diseases |
| Sheril | Serrapeptase | Musculo-Skeletal System | Anti-Inflammatory Enzymes | M09AB | - | Treatment of Musculo-skeletal Disorders |
| Stemin Forte | Betamethasone | Respiratory System | Antiasthmatic & COPD Preparations | H02AB01 | Glucocorticoids | Systemic Corticosteroid Preparations |
| Rozac | Adapalene | Dermatological Therapy | Acne Treatment Preparations | D10AD03 | Topical Retinoid Preparations Used in the Treatment of Acne | - |
| Ripnex | INH, Rifampicin | Anti-Infectives (Systemic) | Anti-TB Agents | J04AM02 | Combination Drugs Used in the Systemic Treatment of Tuberculosis | - |
| Stemin-N | Betamethasone Na phosphate, Neomycin sulphate | Eye | Eye Antiseptics with Corticosteroids | S01CA05 | Corticosteroids in Combination with Antiinfectives | Treatment of Eye Diseases |
| Phenal | Pheniramine maleate | Allergy & Immune System | Antihistamines & Antiallergics | R06AB04 | Substituted Alkylamines Used as Systemic Antihistamines | - |
| Oxo E/E-Dps | Ofloxacin | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S01AE01 | Quinolone Antiinfectives | Treatment of Eye Infections |
| Silzen-C | Chlorhexidine gluconate, Silver sulfadiazine | Dermatological Therapy | Topical Antibiotics | D06BA51 | Topical Sulfonamides Used in the Treatment of Dermatological Diseases | - |
| Sectop | Secnidazole | Anti-Infectives (Systemic) | Antiamoebics | P01AB07 | Nitroimidazole Derivatives Antiprotozoals | Treatment Amoebiasis and other Protozoal Diseases |
| Rabifin | Rabeprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BC04 | Proton Pump Inhibitors | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Quadrimix | Betamethasone dipropionate, Chlorocresol, Gentamicin sulphate, Iodochlorhydroxyquinoline, Tolnaftate | Dermatological Therapy | Topical Corticosteroids | D07CC01 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Swiceff | Cefadroxil | Anti-Infectives (Systemic) | Cephalosporins | J01DB05 | First-generation Cephalosporins | Systemic Treatment of Infections |
| Swil | Pheniramine maleate | Allergy & Immune System | Antihistamines & Antiallergics | R06AB05 | Substituted Alkylamines Used as Systemic Antihistamines | - |
| Suprox | Isoxsuprine HCl | Cardiovascular & Hematopoietic System | Peripheral Vasodilators & Cerebral Activators | C04AA01 | 2-amino-1-phenylethanol Derivative Agents | Peripheral Vasodilators |
| Swidril | Ammon Cl, Diphenhydramine HCl, Menthol, Na citrate | Respiratory System | Cough & Cold Preparations | R05CA10 | Expectorants | Treatment of Wet Cough |
| Spaxin-D | Dexamethasone, Sparfloxacin | Eye | Eye Corticosteroids | S03CA01 | Combinations of Corticosteroids and Antiinfectives Used in Ophthalmologic and Otologic Preparations | - |
| Swiflox-ORD | Ciprofloxacin, Ornidazole | Anti-Infectives (Systemic) | Quinolones | J01RA12 | Combinations of Antibacterials | Systemic Treatment of Infections |
| Swilactin | O-Dps Cyproheptadine HCl, Tricholine citrate, Tricholine citrate /mL. Syr Cyproheptadine HCl | Health Supplements & Food | Appetite Enhancers | A16AX | - | Treatment of Alimentary Tract and Metabolism Problems |
| Swiftax | Cefotaxime | Anti-Infectives (Systemic) | Cephalosporins | J01DD01 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Swiclox-LB | Ampicillin, Cloxacillin Na, Lactobacillus 60 million cells | Anti-Infectives (Systemic) | Penicillins | J01CA51 | Penicillins with Extended Spectrum | Systemic Treatment of Infections |
| Swiflox-D | Ciprofloxacin, Dexamethasone | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S01CA01 | Corticosteroids in Combination with Antiinfectives | Treatment of Eye Diseases |
| Swicof-BG Exp | Bromhexine HCl, Guaiphenesin, Menthol, Salbutamol sulphate | Respiratory System | Antiasthmatic & COPD Preparations | R03AK | - | Treatment of Obstructive Airway Diseases |
| Swiglip-M | Glipizide, Metformin | Hormones | Antidiabetic Agents | A10BD02 | Combinations of Oral Blood Glucose Lowering Drugs | Treatment of Diabetes |
| Sugnl | Glibenclamide | Hormones | Antidiabetic Agents | A10BB01 | Sulfonylureas | Treatment of Diabetes |
| Swispas | Dill oil, Fennel oil, Simeticone | Gastrointestinal & Hepatobiliary System | GIT Regulators, Antiflatulents & Anti-Inflammatories | A03AX | - | Treatment of Functional Bowel Disorders |
| Swiflox | Ciprofloxacin | Anti-Infectives (Systemic) | Quinolones | J01MA02 | Fluoroquinolones | Systemic Treatment of Infections |
| Swimox-LB | Lactobacillus sporogenes 60 million cells, Lactobacillus sporogenes 60 million cells. Per /60 million cells Cap Amoxicillin, Per /60 million cells Cap Amoxicillin | Anti-Infectives (Systemic) | Penicillins | J01CA04 | Penicillins with Extended Spectrum | Systemic Treatment of Infections |
| Swistat | Carbazochrome | Cardiovascular & Hematopoietic System | Haemostatics | B02BX02 | other Systemic Hemostatics | Treatment of Hemorrhage |
| Swispas Tab | Dicyclomine HCl, Paracetamol | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03DC | - | Treatment of Functional Gastrointestinal Disorders |
| Swidol-A | Alfacalcidol, Ca carbonate, Zn | Endocrine & Metabolic System | Agents Affecting Bone Metabolism | A12AX | - | Dietary Supplements |
| Swiminic | Chlorpheniramine maleate, Paracetamol, Phenylephrine HCl | Respiratory System | Cough & Cold Preparations | R01BA53 | Systemic Sympathomimetic Preparations Used as Nasal Decongestants | - |
| Tranee | Tranexamic acid | Cardiovascular & Hematopoietic System | Haemostatics | B02AA02 | Amino Acid Antifibrinolytics | Treatment of Hemorrhage |
| Switralka | Disodium hydrogen citrate | Genito-Urinary System | Other Drugs Acting on the Genito-Urinary System | G04BX | - | Treatment of Urological Problems |
| Toss-K | K nitrate, Sdium monofluorophosphate, Triclosan | Ear & Mouth / Throat | Preparations for Oral Ulceration & Inflammation | A01AA | - | the Prevention of Dental Cavities |
| Tadil | Tadalafil | Genito-Urinary System | Drugs for Erectile Dysfunction & Ejaculatory Disorders | G04BE08 | Drugs Used in Erectile Dysfunction | - |
| Swiztol | Carbamazepine | Central Nervous System | Anticonvulsants | N03AF01 | Carboxamide Derivatives Antiepileptic | - |
| Utgard | Ritodrine | Genito-Urinary System | Drugs Acting on the Uterus | G02CA01 | Sympathomimetics | Labour Repressants |
| Udoxyl | Ursodeoxycholic acid | Gastrointestinal & Hepatobiliary System | Cholagogues, Cholelitholytics & Hepatic Protectors | A05AA02 | Bile Acids | Bile Therapy |
| Toss | Strontium Cl | Ear & Mouth / Throat | Preparations for Oral Ulceration & Inflammation | A01AA | - | the Prevention of Dental Cavities |
| Tetlin | Tetracycline | Anti-Infectives (Systemic) | Tetracyclines | J01AA07 | Tetracyclines | Systemic Treatment of Infections |
| Amibex-TZ | Norfloxacin, Tinidazole | Anti-Infectives (Systemic) | Quinolones | J01RA13 | Combinations of Antibacterials | Systemic Treatment of Infections |
| Aclofen Plus | Aceclofenac, Paracetamol | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB16 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Amibex | Furazolidone, Metronidazole | Anti-Infectives (Systemic) | Antiamoebics | P01AB51 | Nitroimidazole Derivatives Antiprotozoals | Treatment Amoebiasis and other Protozoal Diseases |
| Swithromb | Benzyl nicotinate /, Heparin Na | Cardiovascular & Hematopoietic System | Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics) | C05BA53 | Heparins or Heparinoids Used Topically in Antivaricose Therapy | - |
| Agile-S | Diclofenac K, Paracetamol, Serrapeptase | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB55 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Alltop | Alprazolam | Central Nervous System | Anxiolytics | N05BA12 | Benzodiazepine Derivatives Anxiolytics | Management of Anxiety, Agitation or Tension |
| Agile Inj | Diclofenac Na | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB05 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Alice | Paracetamol | Central Nervous System | Analgesics (Non-Opioid) & Antipyretics | N02BE01 | Anilide Preparations | Relieve Pain and Fever |
| Amyclox-LB | Amoxicillin, Cloxacillin, Lactobacillus sporogenes 120 million cells | Anti-Infectives (Systemic) | Penicillins | J01CR50 | Penicillin Combinations, Including Beta-lactamase Inhibitors | Systemic Treatment of Infections |
| Anaproct | Aloe vera, Alum, Amorphophallus campanulatus, Azadirachta indica, Berberis aristata, Glycyrrhiza glabra, Oyster shell calx, Sapindus trifoliatus, Terminalia chebula | Gastrointestinal & Hepatobiliary System | Anorectal Preparations | A06AX | - | Treatment of Constipation |
| Acsolve-H | Hydrocortisone, Hydroquinone, Tretinoin | Dermatological Therapy | Acne Treatment Preparations | D10AD51 | Topical Retinoid Preparations | Treatment of Acne |
| Vigorvit Forte | Asphaltum, Crocus sativus, Mucuna pruriens, Ocimum sanctum, Orchis mascula, Piper longum, Strychnos nux-vomica, Withania somnifera | Genito-Urinary System | Drugs for Erectile Dysfunction & Ejaculatory Disorders | G04BE | - | Treatment of Urological Problems |
| Swiloric | Allopurinol | Musculo-Skeletal System | Hyperuricemia & Gout Preparations | M04AA01 | Preparations Inhibiting Uric Acid Production | Treatment of Gout |
| Agile-K | Diclofenac K | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB05 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Voranin | Progesterone | Hormones | Oestrogens, Progesterones & Related Synthetic Drugs | G03DA04 | Pregnen (4) Derivative Progestogens | - |
| Alltop-S | Alprazolam, Sertraline | Central Nervous System | Anxiolytics | N06CA | - | Management of Depression |
| Arilif-OZ | Ofloxacin, Ornidazole | Anti-Infectives (Systemic) | Quinolones | J01RA09 | Combinations of Antibacterials | Systemic Treatment of Infections |
| Wax-D | Benzocaine, Chlorbutol, Paradichlorobenzene, Turpentine oil | Ear & Mouth / Throat | Other Ear Preparations | S02DA30 | Analgesic and Anesthetic Agents Used as Otologicals | - |
| Benprost-8 | Argyreia speciosa, Asphaltum, Commiphora mukul, Mimosa pudica, Orchis mascula, Piper nigrum, Stannic sulfide, Tribulus terrestris | Genito-Urinary System | Drugs for Bladder & Prostate Disorders | G04CX | - | Treatment of Benign Prostatic Hypertrophy |
| Aztec-D | Domperidone, Ranitidine HCl | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BX | - | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Anin Inj | Hydroxyprogesterone hexanoate | Hormones | Oestrogens, Progesterones & Related Synthetic Drugs | G03DA03 | Pregnen (4) Derivative Progestogens | - |
| Becmet-N | Beclometasone dipropionate, Neomycin sulphate | Dermatological Therapy | Topical Corticosteroids | D07CC04 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Azithro | Azithromycin | Anti-Infectives (Systemic) | Macrolides | J01FA10 | Macrolides | Systemic Treatment of Infections |
| Arthrill Forte | Boswellia serrata, Curcuma longa, Ricinus communis, Sapindus trifoliatus, Vitex negundo, Zingiber officinale | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AX | - | Treatment of Inflammation and Rheumatism |
| Cafzone | Ceftriaxone Na | Anti-Infectives (Systemic) | Cephalosporins | J01DD04 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Atipam | Lorazepam | Central Nervous System | Anticonvulsants | N05BA06 | Benzodiazepine Derivatives Anxiolytics | Management of Anxiety, Agitation or Tension |
| Becmet-CG | Betamethasone dipropionate, Clotrimazole, Gentamicin sulfate, Lidocaine HCl | Ear & Mouth / Throat | Ear Antiseptics with Corticosteroids | S03CA06 | Combinations of Corticosteroids and Antiinfectives Used in Ophthalmologic and Otologic Preparations | - |
| Candez | Amlodipine | Cardiovascular & Hematopoietic System | Anti-Anginal Drugs | C08CA01 | Dihydropyridine Derivative Selective Calcium-channel Blockers with Mainly Vascular Effects | Treatment of Cardiovascular Diseases |
| Becmet-G | Beclometasone dipropionate, Gentamicin | Dermatological Therapy | Topical Corticosteroids | D07CC04 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Angiguard | Amlodipine | Cardiovascular & Hematopoietic System | Anti-Anginal Drugs | C08CA01 | Dihydropyridine Derivative Selective Calcium-channel Blockers with Mainly Vascular Effects | Treatment of Cardiovascular Diseases |
| Calstat | Ca, Phosphorus | Health Supplements & Food | Supplements & Adjuvant Therapy | A12AX | - | Dietary Supplements |
| Swizyme Cap | Fungal diastase, Lactobacillus 150 million cells, Simeticone | Gastrointestinal & Hepatobiliary System | Digestives | A09AA | - | Digestives |
| Cancap Kit | Fluconazole (1 cap), Tinidazole (2 tabs) | Anti-Infectives (Systemic) | Antifungals | J02AX | - | Systemic Treatment of Mycotic Infections |
| Amy Exp | Ambroxol, Guaifenesin, Loratadine | Respiratory System | Cough & Cold Preparations | R05CB10 | Mucolytics | Treatment of Wet Cough |
| Calswift Tab | Ca, Vit D3 | Vitamins & Minerals | Calcium/with Vitamins | A12AX | - | Dietary Supplements |
| Aftee | Carboxymethylcellulose Na | Eye | Ophthalmic Lubricants | S01XA20 | other Ophthalmologicals | - |
| Anich-3 | Clindamycin, Clotrimazole | Genito-Urinary System | Preparations for Vaginal Conditions | G01A | - | Treatment of Gynecological Infections |
| Cexin | Cefalexin | Anti-Infectives (Systemic) | Cephalosporins | J01DB01 | First-generation Cephalosporins | Systemic Treatment of Infections |
| Cazol-B | Beclometasone dipropionate, Clotrimazole | Dermatological Therapy | Topical Antifungals & Antiparasites | D07CC04 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Cozy | Loratadine | Allergy & Immune System | Antihistamines & Antiallergics | R06AX13 | other Antihistamines for Systemic Use | - |
| Clarie | Clarithromycin | Anti-Infectives (Systemic) | Macrolides | J01FA09 | Macrolides | Systemic Treatment of Infections |
| Cozy-AM | Ambroxol HCl, Guaiphenesin, Loratadine | Respiratory System | Cough & Cold Preparations | R05CA10 | Expectorants | Treatment of Wet Cough |
| Caplor-AS | Aspirin, Clopidogrel | Cardiovascular & Hematopoietic System | Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics) | N02BA01 | Salicylic Acids and Derivatives Agents | Relieve Pain and Fever |
| Ceftop | Cefalexin | Anti-Infectives (Systemic) | Cephalosporins | J01DB01 | First-generation Cephalosporins | Systemic Treatment of Infections |
| Cufex | Chlorpheniramine maleate, Codeine phosphate, Menthol | Respiratory System | Cough & Cold Preparations | R05DA20 | Opium Alkaloids and Derivatives | Cough Suppressant |
| Delin Tab | Theophylline | Respiratory System | Antiasthmatic & COPD Preparations | R03DA04 | Xanthines | Systemic Treatment of Obstructive Airway Diseases |
| Cinclox-S | Ampicillin, Sulbactam | Anti-Infectives (Systemic) | Penicillins | J01CR01 | Penicillin Combinations, Including Beta-lactamase Inhibitors | Systemic Treatment of Infections |
| Clearkin | Permethrin | Dermatological Therapy | Topical Antifungals & Antiparasites | P03AC04 | Pyrethrines, Including Synthetic Compounds Used as Ectoparasiticides | - |
| Derby Cool | Chlorphenesin, Starch, Talc, Zn oxide | Dermatological & Personal Care | Emollients, Cleansers & Skin Protectives | D01AE | - | Topical Treatment of Fungal Infection |
| Clobquad | Clobetasol butyrate, Gentamicin, Iodochlorhydroxyquinoline, Miconazole nitrate | Dermatological Therapy | Topical Corticosteroids | D07CD01 | very Potent (group Iv) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Dicol Gel | Diclofenac diethylammonium 1.16 %, Menthol 5 %, Methyl salicylate 10 %, Oleum lini 3 % | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M02AA15 | Non-steroidal Antiinflammatory Preparations for Topical Use | Treatment of Joint and Muscular Pains |
| Colbutol | Ethambutol | Anti-Infectives (Systemic) | Anti-TB Agents | J04AK02 | other Drugs Used in the Systemic Treatment of Tuberculosis | - |
| Dicoliv T-Gel | Diclofenac diethylamine, Menthol, Methyl salicylate, Oleum lini | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M02AA15 | Non-steroidal Antiinflammatory Preparations for Topical Use | Treatment of Joint and Muscular Pains |
| Distone | Achyranthes aspera, Boerhaavia diffusa, Crataeva nurvala, Dolichos biflorus, Raphanus sativus, Tribulus terrestris | Genito-Urinary System | Other Drugs Acting on the Genito-Urinary System | G04BX | - | Treatment of Urological Problems |
| Dilis | Lisinopril | Cardiovascular & Hematopoietic System | ACE Inhibitors/Direct Renin Inhibitors | C09AA03 | Ace Inhibitors | Treatment of Cardiovascular Disease |
| Cozy Kid | Chlorpheniramine maleate, Paracetamol, Phenylephrine HCl | Respiratory System | Cough & Cold Preparations | R01BA53 | Systemic Sympathomimetic Preparations Used as Nasal Decongestants | - |
| Diaze-P | Diazepam, Propranolol | Cardiovascular & Hematopoietic System | Beta-Blockers | C07AA05 | Non-selective Beta-blocking Agents | Treatment of Cardiovascular Diseases |
| E-Cold | Caffeine, Chlorphenamine maleate, Paracetamol | Respiratory System | Cough & Cold Preparations | N02BE51 | Anilide Preparations | Relieve Pain and Fever |
| Decaneurophen | Nandrolone decanoate | Endocrine & Metabolic System | Anabolic Agents | A14AB01 | Estren Derivative Anabolic Steroids Used as Systemic Anabolic Agents | - |
| Etoxin-B | Bromhexine HCl, Terbutaline sulphate | Respiratory System | Antiasthmatic & COPD Preparations | R03CC53 | Adrenergics for Systemic Use, Selective Beta-2-adrenoreceptor Agonists | Treatment of Obstructive Airway Diseases |
| Enbenol | Albendazole | Anti-Infectives (Systemic) | Anthelmintics | P02CA03 | Benzimidazole Derivative Agents | Antinematodal |
| Dicoliv-S | Diclofenac Na, Serratiopeptidase (EC) | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB55 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Dopin | Dosulepin | Central Nervous System | Antidepressants | N06AA16 | Non-selective Monoamine Reuptake Inhibitors | Management of Depression |
| Elucin Crm | Erythromycin | Dermatological Therapy | Acne Treatment Preparations | D10AF02 | Topical Antiinfective Preparations Used in the Treatment of Acne | - |
| Evitop | Vit E | Vitamins & Minerals | Vitamins A, D & E | A11HA03 | other Plain Vitamin Preparations | Dietary Supplements |
| Ferritop | Fe fumarate, Folic acid, Vit B12, Vit C, Zn sulphate | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE | - | Treatment of Anemia |
| Ferritop Iron Tonic | Cyanocobalamin, Fe ammon citrate, Folic acid, Sorbitol | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE | - | Treatment of Anemia |
| Feritin | Fe | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03A | - | Treatment of Anemia |
| Dicoliv | Diclofenac Na | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB05 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Dicol-S | Diclofenac Na, Serratiopeptidase | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01BX | - | Treatment of Inflammation and Rheumatism |
| Gdsafe | Colistin sulphate | Anti-Infectives (Systemic) | Other Antibiotics | J01XB01 | Polymyxins | Systemic Treatment of Infections |
| Ferrofit | Cyanocobalamin, Fe ammon citrate, Folic acid, Pyridoxine HCl, Sorbitol | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE | - | Treatment of Anemia |
| Cetin | Cetirizine | Allergy & Immune System | Antihistamines & Antiallergics | R06AE07 | Piperazine Derivatives Used as Systemic Antihistamines | - |
| Excef-DT | Cefixime | Anti-Infectives (Systemic) | Cephalosporins | J01DD08 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Eleben | Albendazole | Anti-Infectives (Systemic) | Anthelmintics | P02CA03 | Benzimidazole Derivative Agents | Antinematodal |
| Genta Swift-D | Dexamethasone Na phosphate, Gentamycin | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S03CA01 | Combinations of Corticosteroids and Antiinfectives Used in Ophthalmologic and Otologic Preparations | - |
| Gabin-M | Gabapentin, Mecobalamin | Central Nervous System | Drugs for Neuropathic Pain | N06BX | - | Cns Stimulant |
| Frutop Tonic | Fe choline citrate, L-Lysine monohydroCl, Manganese Cl, MgCl 2, Niacinamide, Protein hydrolysate 20%, Sucrose, Zn sulphate | Nutrition | Enteral/Nutritional Products | V06DX | - | General Nutrients |
| Expodox-CV | Clavulanic acid, Clavulanic acid . Per 200/ Tab Cefpodoxime, Per 100/ Tab Cefpodoxime | Anti-Infectives (Systemic) | Cephalosporins | J01DD64 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Hemforte | Fe fumarate, Folic acid, Vit B12 | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE01 | Iron in other Combinations | Treatment of Anemia |
| Doloswift | Piroxicam | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AC01 | Non-steroidal Antiinflammatory and Antirheumatic Products, Oxicams | - |
| Glufit | Pioglitazone | Hormones | Antidiabetic Agents | A10BG03 | Thiazolidinediones | Treatment of Diabetes |
| Ferritop-SR | dried, Ferrous sulphate, Folic acid | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AD | - | Treatment of Anemia |
| Haemoprotex | Cyanocobalamin, Fe choline citrate, Folic acid, Protein hydrolysate 20%, Pyridoxine HCl, Thiamine HCl | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE | - | Treatment of Anemia |
| I-Top | Boric acid 1.25 %, Chlorbutanol 0.35 %, Chlorpheniramine maleate 0.01 %, NaCl 0.05 %, Naphazoline HCl 0.056 %, Zn sulphate 0.12 % | Eye | Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories | S01GX | - | Ophthalmologic Antiallergics |
| Hycort Crm | Hydrocortisone acetate | Dermatological Therapy | Topical Corticosteroids | D07AA02 | Weak (group I) Corticosteroids | Treatment of Dermatological Diseases |
| Fexidine | Fexofenadine HCl | Allergy & Immune System | Antihistamines & Antiallergics | R06AX26 | other Antihistamines for Systemic Use | - |
| Key | Ketorolac trometamol | Eye | Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories | S01BC05 | Non-steroidal Antiinflammatory Agents | Treatment of Inflammation of the Eye |
| Ind-Orange | Fe ammon citrate, Folic acid, Vit B12 | Vitamins & Minerals | Vitamins & Minerals (Pre & Post Natal) / Antianemics | B03AE01 | Iron in other Combinations | Treatment of Anemia |
| Liza | Lansoprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BC03 | Proton Pump Inhibitors | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Faxtin-A | Alprazolam, Fluoxetine HCl | Central Nervous System | Antidepressants | N06CA03 | Antidepressants in Combination with Psycholeptics | - |
| Link Gel | Lincomycin HCl | Dermatological Therapy | Topical Antibiotics | D06AX | - | Treatment of Dermatological Diseases |
| Indilac | Bacillus mesentericus 1 million cells, Clostridium butyricum 2 million cells, Lactobacillus sporogenes 50 million cells, Strep faecalis 30 million cells | Gastrointestinal & Hepatobiliary System | Antidiarrheals | A07FA51 | Antidiarrheal Microorganisms | Treatment of Diarrhea |
| Livasa | Andrographis paniculata, Cichorium intybus, Eclipta alba, Milk thistle, Phyllanthus niruri, Picrorhiza kurroa, Piper longum, Solanum nigrum, Tamarix gallica, Tephrosia purpurea | Gastrointestinal & Hepatobiliary System | Cholagogues, Cholelitholytics & Hepatic Protectors | A05C | - | Bile and Liver Therapy |
| Glitter-M | Metformin, Metformin . Per 30/ Tab Pioglitazone, Per 15/ Tab Pioglitazone | Hormones | Antidiabetic Agents | A10BD05 | Combinations of Oral Blood Glucose Lowering Drugs | Treatment of Diabetes |
| Igardex | Camphor, Chlorpheniramine maleate, Menthol, Naphazoline HCl, Phenylephrine | Eye | Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories | S01GA51 | Sympathomimetics Used as Ophthalmologic Decongestants | - |
| Ergest | Ethinyloestradiol, Levonorgestrel | Hormones | Oestrogens, Progesterones & Related Synthetic Drugs | G03AA07 | Progestogens and Estrogens in Fixed Combinations | Systemic Contraceptives |
| Foot Care | Lactic acid, Liqd paraffin, Propylene glycol, Urea | Dermatological & Personal Care | Emollients, Cleansers & Skin Protectives | D11AX | - | Treatment of Dermatological Diseases |
| Inorine | Drotaverine | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03AD02 | Papaverine and Derivatives | Treatment of Functional Bowel Disorders |
| Indcef-DT | Cefixime | Anti-Infectives (Systemic) | Cephalosporins | J01DD08 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Lopram | Citalopram | Central Nervous System | Antidepressants | N06AB04 | Selective Serotonin Reuptake Inhibitors | Management of Depression |
| Genta Swift | Gentamicin | Anti-Infectives (Systemic) | Aminoglycosides | J01GB03 | other Aminoglycosides | Systemic Treatment of Infections |
| Lospot | Losartan K | Cardiovascular & Hematopoietic System | Angiotensin II Antagonists | C09CA01 | Angiotensin Ii Receptor Blockers (arbs) | Treatment of Cardiovascular Disease |
| Mef-T | Mefenamic acid, Tizanidine | Musculo-Skeletal System | Muscle Relaxants | M03BX | - | Muscle Relaxants |
| Nelsid T-Gel | Capsaicin, Menthol, Methyl salicylate, Nimesulide, Oeum lini | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M02AA26 | Non-steroidal Antiinflammatory Preparations for Topical Use | Treatment of Joint and Muscular Pains |
| Metoclop | Metoclopramide | Gastrointestinal & Hepatobiliary System | Antiemetics | A03FA01 | Propulsives | Treatment of Functional Gastrointestinal Disorders |
| Neo Swiflox-FC | Clotrimazole, Fluocinolone, Methylparaben, Neomycin, Propylparaben sodium | Dermatological Therapy | Topical Anti-Infectives with Corticosteroids | D07CC02 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Netazox | Nitazoxanide | Anti-Infectives (Systemic) | Antiamoebics | P01AX11 | other Agents Used in the Treatment Amoebiasis and other Protozoal Diseases | - |
| Lospot-H | Hydrochlorothiazide, Losartan K | Cardiovascular & Hematopoietic System | Angiotensin II Antagonists | C09DA01 | Angiotensin Ii Receptor Blockers (arbs) in Combination with Diuretics | Treatment of Cardiovascular Disease |
| Mycobal | Mecobalamin | Central Nervous System | Nootropics & Neurotonics/Neurotrophics | B03BA05 | Vitamin B12 (cyanocobalamin and Analogues) | Treatment of Anemia |
| Lycoswift | Lycopene 6%, Selenium, Vit E | Vitamins & Minerals | Vitamins &/or Minerals | V06DX | - | General Nutrients |
| Nelsid Forte | Chlorzoxazone, Nimesulide, Paracetamol | Musculo-Skeletal System | Muscle Relaxants | M03BB53 | Oxazol, Thiazine, and Triazine Derivative Agents | Centrally-acting Muscle Relaxants |
| Neurobex-B | Biotin, Ca pantothenate, Folic acid, Niacinamide, Nicotinic acid, Pyridoxine HCl, Riboflavin, Thiamine mononitrate, Vit B12 | Vitamins & Minerals | Calcium/with Vitamins | A11EA | - | Dietary Supplements |
| Malswift | Chloroquine phosphate | Anti-Infectives (Systemic) | Antimalarials | P01BA01 | Aminoquinoline Antimalarials | - |
| LTC Kit | Clarithromycin (2 tabs), Lansoprazole (2 caps), Tinidazole (2 tabs) | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BD | - | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Mobyle Gel | Diclofenac diethylamine | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M02AA15 | Non-steroidal Antiinflammatory Preparations for Topical Use | Treatment of Joint and Muscular Pains |
| Nelsid-MR | Nimesulide, Tizanidine | Musculo-Skeletal System | Muscle Relaxants | M03BX | - | Muscle Relaxants |
| Metswift | Metformin HCl | Hormones | Antidiabetic Agents | A10BA02 | Biguanides | Treatment of Diabetes |
| Neurophen Crm | Chlorpheniramine maleate, Diethylamine salicylate, Menthol, Mephenesin, Methyl nicotinate, Methyl salicylate, Turpentine oil | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M02AA | - | Treatment of Joint and Muscular Pains |
| Neurospas-CD | Chlordiazepoxide, Clidinium Br, Dicyclomine HCl | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03CA | - | Treatment of Functional Gastrointestinal Disorders |
| Merigel | Magaldrate, Simethicone | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02AF01 | Antacids with Antiflatulents | - |
| Quiet | Alprazolam | Central Nervous System | Anxiolytics | N05BA12 | Benzodiazepine Derivatives Anxiolytics | Management of Anxiety, Agitation or Tension |
| Met | Metronidazole | Anti-Infectives (Systemic) | Antiamoebics | P01AB01 | Nitroimidazole Derivatives Antiprotozoals | Treatment Amoebiasis and other Protozoal Diseases |
| Jovin-M | Methylcobalamin, Pregabalin | Central Nervous System | Drugs for Neuropathic Pain | N02BF02 | Gabapentinoids | Relieve Pain and other Conditions |
| Neurobex | Ca pantothenate, Folic acid, Lactobacillus acidophilus 100 million cells, Vit B1, Vit B12, Vit B2, Vit B6, Vit C | Vitamins & Minerals | Vitamins &/or Minerals | A11JC | - | Dietary Supplements |
| ORD | Ornidazole | Anti-Infectives (Systemic) | Antiamoebics | P01AB03 | Nitroimidazole Derivatives Antiprotozoals | Treatment Amoebiasis and other Protozoal Diseases |
| Neurospas | Dicyclomine HCl, Paracetamol | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03DC | - | Treatment of Functional Gastrointestinal Disorders |
| Neuroswift | Mecobalamin | Central Nervous System | Nootropics & Neurotonics/Neurotrophics | B03BA05 | Vitamin B12 (cyanocobalamin and Analogues) | Treatment of Anemia |
| Nozy | Xylometazoline | Respiratory System | Nasal Decongestants & Other Nasal Preparations | R01AA07 | Topical Sympathomimetic Agents Used as Nasal Decongestants | - |
| Neurophen | Nandrolone phenylpropionate | Endocrine & Metabolic System | Anabolic Agents | A14AB01 | Estren Derivative Anabolic Steroids Used as Systemic Anabolic Agents | - |
| Pentagon | Pantoprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BC02 | Proton Pump Inhibitors | Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) |
| Oxo-ORD | Ornidazole, Ornidazole . O-Susp Ofloxacin, Tab Ofloxacin | Anti-Infectives (Systemic) | Quinolones | J01RA09 | Combinations of Antibacterials | Systemic Treatment of Infections |
| Neurobex O-Dps | Mecobalamin, Niacinamide, Pyridoxine HCl, Riboflavin, Thiamine HCl, Vit A palmitate, Vit D3 | Vitamins & Minerals | Vitamin B-Complex / with C | A11JA | - | Dietary Supplements |
| Norrit Susp | Metronidazole, Norfloxacin | Anti-Infectives (Systemic) | Quinolones | J01RA14 | Combinations of Antibacterials | Systemic Treatment of Infections |
| Oxo-D | Dexamethasone, Ofloxacin | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S01CA01 | Corticosteroids in Combination with Antiinfectives | Treatment of Eye Diseases |
| Pentazen | Paracetamol, Tramadol | Central Nervous System | Analgesics (Opioid) | N02AJ13 | Opioids in Combination with other Non-opioid Analgesics | Relieve Pain |
| Ozo-D | Domperidone, Omeprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A03FA03 | Propulsives | Treatment of Functional Gastrointestinal Disorders |
| Phena | Promethazine | Gastrointestinal & Hepatobiliary System | Antiemetics | R06AD02 | Phenothiazine Derivatives Used as Systemic Antihistamines | - |
| Qest | Atorvastatin | Cardiovascular & Hematopoietic System | Dyslipidaemic Agents | C10AA05 | Hmg Coa Reductase Inhibitors | Treatment of Hyperlipidemia |
| Silzen | Silver sulfadiazine | Dermatological Therapy | Topical Antibiotics | D06BA01 | Topical Sulfonamides Used in the Treatment of Dermatological Diseases | - |
| Roxy | Roxithromycin | Anti-Infectives (Systemic) | Macrolides | J01FA06 | Macrolides | Systemic Treatment of Infections |
| Phena-P | Paracetamol, Promethazine HCl | Central Nervous System | Analgesics (Non-Opioid) & Antipyretics | N02BE51 | Anilide Preparations | Relieve Pain and Fever |
| Reban | Avobenzone, Octyl methoxycinnamate, Oxybenzone | Dermatological & Personal Care | Emollients, Cleansers & Skin Protectives | D02BA | - | Protection against Uv-radiation |
| Setil | Prochlorperazine mesilate | Central Nervous System | Antivertigo Drugs | N05AB04 | Phenothiazine Antipsychotics with Piperazine Structure | - |
| Rucko | Racecadotril | Gastrointestinal & Hepatobiliary System | Antidiarrheals | A07XA04 | other Antidiarrheals | - |
| Predyl-O | Ofloxacin, Prednisolone acetate | Eye | Eye Anti-Infectives & Antiseptics | S01CA02 | Corticosteroids in Combination with Antiinfectives | Treatment of Eye Diseases |
| Ovidine OM-Sol | Povidone iodine | Ear & Mouth / Throat | Preparations for Oral Ulceration & Inflammation | R02AA15 | Antiseptics Used in Throat Preparations | - |
| Stemin-MU | Betamethasone dipropionate, Mupirocin | Dermatological Therapy | Topical Antibiotics | D07CC01 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Oxo | Ofloxacin | Anti-Infectives (Systemic) | Quinolones | J01MA01 | Fluoroquinolones | Systemic Treatment of Infections |
| Spaxin | Sparfloxacin | Anti-Infectives (Systemic) | Quinolones | J01MA09 | Fluoroquinolones | Systemic Treatment of Infections |
| OLO | Olopatadine | Eye | Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories | S01GX09 | other Ophthalmologic Antiallergics | - |
| Swicof Exp | Ammon Cl, Bromhexine HCl, Dextromethorphan HBr, Menthol | Respiratory System | Cough & Cold Preparations | R05FA02 | Combinations of Opium Derivatives Cough Suppressants and Expectorants | Treatment of Cough |
| Oxter | Oxytetracycline | Anti-Infectives (Systemic) | Tetracyclines | J01AA06 | Tetracyclines | Systemic Treatment of Infections |
| Pulse-B | Chloramphenicol, Polymyxin B | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S01AA30 | Antibiotics | Treatment of Eye Infections |
| Stemin | Betamethasone Na phosphate | Respiratory System | Antiasthmatic & COPD Preparations | H02AB01 | Glucocorticoids | Systemic Corticosteroid Preparations |
| Sugnl-M | Glibenclamide, Metformin | Hormones | Antidiabetic Agents | A10BD02 | Combinations of Oral Blood Glucose Lowering Drugs | Treatment of Diabetes |
| Swifix | Cefixime | Anti-Infectives (Systemic) | Cephalosporins | J01DD08 | Third-generation Cephalosporins | Systemic Treatment of Infections |
| Swidox | Doxycycline hyclate | Anti-Infectives (Systemic) | Tetracyclines | J01AA02 | Tetracyclines | Systemic Treatment of Infections |
| Swicee | Ascorbic acid | Vitamins & Minerals | Vitamin C | A11GA01 | Ascorbic Acid (vitamin C) | Dietary Supplements |
| Swiflox-TZ | Ciprofloxacin, Tinidazole | Anti-Infectives (Systemic) | Quinolones | J01RA11 | Combinations of Antibacterials | Systemic Treatment of Infections |
| Stemin-GM | Betamethasone dipropionate, Gentamicin, Miconazole nitrate | Dermatological Therapy | Topical Anti-Infectives with Corticosteroids | D07CC01 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Stedex | Chloramphenicol, Dexamethasone Na phosphate | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S03CA01 | Combinations of Corticosteroids and Antiinfectives Used in Ophthalmologic and Otologic Preparations | - |
| Swilax | Bisacodyl | Gastrointestinal & Hepatobiliary System | Laxatives, Purgatives | A06AB02 | Contact Laxatives | - |
| Swimet | Glimepiride, Metformin HCl | Hormones | Antidiabetic Agents | A10BD02 | Combinations of Oral Blood Glucose Lowering Drugs | Treatment of Diabetes |
| Sucracid | Sucralfate | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A02BX02 | other Drugs Used in the Treatment of Peptic Ulcer and Gastro-oesophageal Reflux Disease (gerd) | - |
| Switus | Bromhexine HCl, Chlorpheniramine maleate, Guaiphenesin, Paracetamol | Respiratory System | Cough & Cold Preparations | R05CB10 | Mucolytics | Treatment of Wet Cough |
| Swispas Inj | Dicyclomine HCl | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03AA07 | Synthetic Anticholinergics, Esters with Tertiary Amino Group | Treatment of Functional Bowel Disorders |
| Swispas-M | Dicyclomine HCl, Mefenamic acid | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03ED | - | Treatment of Functional Gastrointestinal Disorders |
| Swilac | Lactulose | Gastrointestinal & Hepatobiliary System | Laxatives, Purgatives | A06AD11 | Osmotically Acting Laxatives | - |
| Swizyme | Diastase, Pepsin | Gastrointestinal & Hepatobiliary System | Digestives | A09AA | - | Digestives |
| Switob | Tobramycin | Eye | Eye Anti-Infectives & Antiseptics | S01AA12 | Antibiotics | Treatment of Eye Infections |
| Swiflox-FC | Ciprofloxacin HCl, Clotrimazole, Fluocinolone acetonide | Dermatological Therapy | Topical Anti-Infectives with Corticosteroids | D07CC02 | Potent (group Iii) Corticosteroids, in Combination with Antibiotics | Treatment of Dermatological Diseases |
| Swiflox E/E-Dps | Ciprofloxacin HCl | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S03AA07 | Antiinfectives Used in Ophthalmologic and Otologic Preparations | - |
| Swimox | Amoxicillin | Anti-Infectives (Systemic) | Penicillins | J01CA04 | Penicillins with Extended Spectrum | Systemic Treatment of Infections |
| Swiscab | Lindane | Dermatological Therapy | Topical Antifungals & Antiparasites | P03AB02 | Chlorine-containing Agents Used as Ectoparasiticides | - |
| Swithro | Azithromycin | Anti-Infectives (Systemic) | Macrolides | J01FA10 | Macrolides | Systemic Treatment of Infections |
| Swidex | Ammon Cl, Bromhexine HCl, Dextromethorphan HBr, Menthol | Respiratory System | Cough & Cold Preparations | R05FA02 | Combinations of Opium Derivatives Cough Suppressants and Expectorants | Treatment of Cough |
| Swizyme Dps | Fungal diastase, Pepsin | Gastrointestinal & Hepatobiliary System | Digestives | A09AA | - | Digestives |
| Telhim-AM | Amlodipine, Telmisartan | Cardiovascular & Hematopoietic System | Angiotensin II Antagonists | C09DB04 | Angiotensin Ii Receptor Blockers (arbs) and Calcium Channel Blockers | Treatment of Cardiovascular Disease |
| Swigrain | Caffeine, Ergotamine tartrate, Paracetamol, Prochlorperazine maleate | Central Nervous System | Antimigraine Preparations | N02CA52 | Ergot Alkaloids Preparations | Relieve Migraine |
| Toss M-Paint | Alum /, Camphor, Iodine, K iodide, Menthol, Tannic acid, Thymol | Ear & Mouth / Throat | Preparations for Oral Ulceration & Inflammation | A01AD | - | Treatment of Diseases of the Mouth |
| Swiftspas | Drotaverine, Nimesulide | Gastrointestinal & Hepatobiliary System | Antispasmodics | A03DC | - | Treatment of Functional Gastrointestinal Disorders |
| Swiclox | Cap A mpicillin, Cloxacillin, Cloxacillin . Per 500/ Pwd-Inj Ampicillin, Cloxacillin Na . Per 250/ Pwd-Inj Ampicillin | Anti-Infectives (Systemic) | Penicillins | J01CR50 | Penicillin Combinations, Including Beta-lactamase Inhibitors | Systemic Treatment of Infections |
| Toss-K M-Wash | Chlorhexidine gluconate | Ear & Mouth / Throat | Preparations for Oral Ulceration & Inflammation | A01AB03 | Local Antiinfective and Antiseptic Preparations | Treatment of Diseases of the Mouth |
| Turbo Cough | Cetirizine diHCl, Dextromethorphan HBr, Menthol /mL, Pseudoephedrine HCl | Respiratory System | Cough & Cold Preparations | R05DA20 | Opium Alkaloids and Derivatives | Cough Suppressant |
| Ulsore Gel | Choline salicylate 8.7 %, Lignocaine hydrochloride | Ear & Mouth / Throat | Preparations for Oral Ulceration & Inflammation | A01AD | - | Treatment of Diseases of the Mouth |
| Wax-CL | Beclomethasone dipropionate, Chloramphenicol, Clotrimazole, Lignocaine | Ear & Mouth / Throat | Ear Anti-Infectives & Antiseptics | S02CA | - | Treatment of Ear Diseases |
| Vomigo | Ondansetron | Gastrointestinal & Hepatobiliary System | Antiemetics | A04AA01 | Serotonin (5ht3) Antagonists | the Prevention of Nausea and Vomiting |
| Vigorvit | Asparagus adscendens, Asparagus racemosus, Asphaltum, Caryophyllus aromaticus, Mucuna pruriens, Myristica fragrans, Myristica officinalis, Pueraria tuberosa, Putranjiva roxburghii | Genito-Urinary System | Drugs for Erectile Dysfunction & Ejaculatory Disorders | G04BE | - | Treatment of Urological Problems |
| Topclav | KÂ Clavulanate, KÂ Clavulanate . Per D-Syr Amoxicillin, Per Tab Amoxicillin | Anti-Infectives (Systemic) | Penicillins | J01CR02 | Penicillin Combinations, Including Beta-lactamase Inhibitors | Systemic Treatment of Infections |
| Aclofen | Aceclofenac | Central Nervous System | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | M01AB16 | Acetic Acid Derivatives and Related Substances of Non-steroidal Antiinflammatory and Antirheumatic Products | - |
| Pentagon-D | Domperidone, Pantoprazole | Gastrointestinal & Hepatobiliary System | Antacids, Antireflux Agents & Antiulcerants | A03FA03 | Propulsives | Treatment of Functional Gastrointestinal Disorders |
| Caplor-AS | Aspirin, Clopidogrel | Cardiovascular & Hematopoietic System | Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics) | B01AC30 | Platelet Aggregation Inhibitors Excluding Heparin | Treatment of Thrombosis |
| Jovin-M | Methylcobalamin, Pregabalin | Central Nervous System | Drugs for Neuropathic Pain | N06BX | Other Psychostimulants and Nootropics | Cns Stimulant |

## Key Metrics

Not Available

## Related Party Disclosure

Not Available

## Shareholders

| SHAREHOLDER NAME | VALUE (%) | TYPE OF SHARE |
|---|---|---|
| Essix Biosciences Limited | 31.4 | Equity Shares |

| SHAREHOLDER NAME | VALUE (%) | TYPE OF SHARE |
|---|---|---|
| Essix Biosciences Limited | 31.4 | Equity |
| S. R. Mehta | 3.76 | Equity |
| Gopal Munjal | 3.61 | Equity |
| V.R. Mehta | 3.55 | Equity |
| Sunita Jain | 3.35 | Equity |
| Late Neera Mehta | 2.86 | Equity |
| Rameshkumar Javerchand Jain | 2 | Equity |
| Justin Pharmaceuticals Private Limited | 1.59 | Equity |
| Gravity Systems Private Limited | 1.38 | Equity |
| Huf | 1.37 | Equity |
| Panchkula Finvest Private Limited | 1.31 | Equity |
| Ravi Mehta | 1.17 | Equity |
| N.R. Munjal | 1.13 | Equity |
| Excel Motors Private Limited | 1.08 | Equity |
| Neeta Munjal | 1.07 | Equity |
| Nidhi Munjal | 0.93 | Equity |
| Himanshu Jain | 0.91 | Equity |
| Meenakshi Mehta | 0.74 | Equity |
| Annie Mehta | 0.29 | Equity |
| Sahil Munjal | 0.24 | Equity |
| Rishav Mehta | 0.21 | Equity |
| Saurabh Munjal | 0.1 | Equity |
| Ishav Mehta | 0.08 | Equity |
| Deepti Munjal | 0.06 | Equity |
| Bhanavi Mehta | 0.06 | Equity |
| Clearing Members | 0.04 | Equity |
| Divya Munjal | 0.03 | Equity |
| Daksh Mehta | 0 | Equity |

| SHAREHOLDER NAME | VALUE (%) | TYPE OF SHARE |
|---|---|---|
| Promoters | 55.6 | Equity |
| Non Promoters | 44.4 | Equity |

## Residence of Shareholders

Not Available

## Segment Reporting

Not Available

## Geographic Distribution

Not Available

## Key Milestones

| DATE | MILESTONE |
|---|---|
| Jul 2025 | NCLT approved the amalgamation of Ind Swift Limited with Ind Swift Laboratories Limited . |
| Aug 2025 | Ind-Swift Laboratories Ltd agreed to acquire Ind-Swift Limited for INR 708 million . |
| Mar 2025 | Concerns raised over Ind-Swift Laboratories' investment in TruCap Finance due to stock declines . |
| Sep 2023 | Board approved slump sale of API & CRAMS business to Synthimed Labs for â‚¹1650 Crores . |
| Sep 2023 | Approved merger of Ind-Swift Lab & Ind-Swift Limited . |
| 2013 | Received regulatory approvals from EDQM, ANVISA, NOM, Cofepris, ANSM France . |
| 2012 | Received USFDA Approval for 5 major products . |
| 2011 | Completed 25 years of commitment to health . |
| 2010 | Established subsidiaries in Dubai (Ind-Swift Middle East FZE) and Singapore . |
| 2010 | Received KFDA Approval for 2 major products . |
| 2009 | Received PMDA Approval . |
| 2008 | Ventured into Phyto-Chemicals Business . |
| 2007 | Received USFDA Approval for First Product . |
| 2006 | Raised US $ 10 Mn through GDR . |
| 2005 | Second Plant at Jammu started Production . |
| 2004 | Maiden Dividend . |
| 2004 | Incorporated Ind-Swift Laboratories Inc in USA . |
| 2004 | Launched Acamprosate, Ezetimibe, Anastrazole and Nitazoxanide . |
| 1998 | First Plant at Derabassi, Punjab Commenced Production . |
| 1997 | IPO for Rs 75 Million Raised . |
| 1995 | Ind-Swift is incorporated with PSIDC . |
| 1986 | Established by the Jains, Mehtas, and Munjals . |
| 1986 | Incorporated as a limited company on June 6, 1986 . |

## Patents

Not Available

## Partners

Roche Diagnostics

## Clients

TEVA, Mylan, Actavis, Stada, Ratiopharm, Dar-al-dawa DAD (jordan), ITOCHU (japan)

## Awards and Certifications

- Most Promising Entrant into the Big League Award at 5th Annual Pharmaceutical Leadership Summit & Business Leadership Award 2012
- ISO 9001-2008 by BSI (British Standards Institution)
- R&D Centre approved & recognized by DSIR and is also USFDA Registered
- IDMA Quality Excellence Certified
- Winner of Pharma Pulse Awards for 3 consecutive years (2002-2005)
- Punjab Rattan Award
- Ludhiana Management Association Award
- Bharat Udyog Rattan Award
- Awarded as the most promising Pharmaceutical Company at 8th Healthcare Forum 2018
- ISO 9001-2008
- WHO-GMP
- TGA - Australia
- USFDA
- MHRA - UK
- NDA - Uganda
- TFDA - Tanzania
- UAEC Registration
- DACA - Ethiopia
- GMP - Yemen
- GMP - Ivory Coast


## Market Size

| SOURCE | MARKET | REGION | DATE | CURRENT MARKET SIZE | GROWTH (%) |
|---|---|---|---|---|---|
| Expert Market Research | India Plant Based Nutraceuticals Market Report | India | 2025 | $ 100M (2024) | 15 |
| TechSci Research | India Nutraceutical Market | India | 2024 | $ 6.11B (2024) | 11.39 |
| TechSci Research | Nutraceuticals Cdmo | Global | 2024 | $ 34.09B (2023) | 7.87 |
| Grand View Research | India Nutritional Supplement Market | India | 2024 | $ 68.43B (2030) | 8.1 |
| Grand View Research | Nutraceutical | Global | 2024 | $ 712.97B (2023) | 8.4 |

## SWOT

### Strengths
- Net profit rose 832.98% to â‚¹8.77 crore in June 2025 quarter .
- Sales rose 360.45% to â‚¹152.73 crore in the quarter ended June 2025 .
- FII shareholding increased by 2179.75% in the past year .

### Weaknesses
- Net sales dropped from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025 .
- Operating profit was INR -19.39 crore in March 2025, compared to INR 303.06 crore in March 2024 .
- Earnings per share decreased from INR 78.38 to INR 36.44 .

### Opportunities
- India pharma market is expected to grow from USD 25 billion in 2024 to USD 50 billion by 2030 .
- Online pharmacies are advancing at a 7.30% CAGR to 2030 .
- India's pharmaceutical exports increased by 8.36% from July 2023 to July 2024 .

### Threats
- The company has delivered a poor sales growth of -6.35% over past five years .
- Standalone net profit declined by 69.92% year-on-year during the June quarter .
- Price action analysis of IndSwift (INDSWFTLAB) based on a short term time period is negative .



## Global Presence

India, Afghanistan, Australia, Canada, Costa Rica, Dar-al-dawa (jordan), Ethiopia, Guyana, Honduras, Iran, Iraq, Japan, Jamaica, Malaysia, Mexico, Panama, Peru, Philippines, Russia, Serbia, Tanzania, Taiwan, United Arab Emirates, United Kingdom, United States, Uganda, Venezuela

## Future Plan

- Ind Swift plans to invest Rs. 100 crore in expansion, setting up three units in Punjab, Himachal Pradesh, and Jammu & Kashmir, expected to be completed within nine months.
- The company anticipates a three-fold capacity expansion leading to a 40% growth in sales and profits.
- Ind Swift is expanding its product range by launching new divisions including Diagnozis for medical devices and Resurgence for anesthesiology and oncology.
- In 2007, the company opened its first overseas office in New Jersey, USA, marking its geographical expansion.
- The new formulation facility in Jammu is nearing completion, while the new units in Punjab and Himachal Pradesh are expected to be operational by September 2005.


## Details

Links: Â Â Â Â Â Â Â Â Â Â 

Founded: **1986**

Headquarters: **781INDUSTRIAL AREA PHASE II CHANDIGARH CH 160002 IN**

Domain: **Pharmaceuticals**

Segment: **Pharmaceuticals Manufacturing & Marketing**

Sub-segment: **Ethical & Generic Drugs**

Customer Base: **B2B**

Business Activity: **Manufacturing; Distribution; R&D Other (pharmaceuticals)**

## Ownership

Type: **Investor-held**

All Investors: **Ind-Swift Laboratories Limited**

Last Funding Date: **Aug 2025**

Last Funding Amount: **$ 8.58 M**

Total Funding Amount: **$ 8.58 M**

## Board Members

#### Team

- Himanshu Jain (Director)
- Navrattan Munjal (Director)
- Rishav Mehta (Additional Director)
- Arun Seth (CFO)
- Puneet Khurana (Company Secretary)
- Gopal Munjal (Managing Director)
- Sanjeev Rai Mehta (Whole-time director)
- Vikrant Rai Mehta (Whole-time director)


#### Independent Board Member

- Subodh Gupta (Director)
- Prabhat Khurana (Director)
- Jagvir Singh Ahluwalia (Director)
- Subhash Chander Galhotra (Director)
- Anoop Michra (Director)
- Bhupinder Singh (Director)

## Leadership

* Gopal Munjal (Managing Director & CEO)
* Sanjeev Rai Mehta (Chairman)
* Gagan Aggarwal (Chief Finance Officer)
* Alias (Cfo)
* Nav Rattan Munjal (Director)
* Vikrant Rai Mehta (Joint Managing Director)
* Himanshu Jain (Director)
* Rishav Mehta (Director)
* S.C. Galhotra (Independent Director)
* J.S. Ahluwalia (Independent Director)
* S.P. Sharma (Independent Director)
* V.K. Arora (Independent Director)
* Bhupinder Singh (Independent Director)
* Anil Agrawal (Chief Operating Officer)
* Lalit Goyal (Vice President - Accounts & Costing)
* Varun Chhabra (Senior Vice President - International Marketing)
* Pardeep Verma (Vice President - Corporate Affairs)
* Akash Deep Sharma (Vice President - Human Resources)
* Ashok Kothari (General Manager - Information Technology)
* Vivek Mishra (Vice President - Ethical Business (India))
* Viren Ramkrishna Nagar (Vice President - Generic Business (India))
* Pratik Kumar (Vice President - R&D)
* Satbir Singh (Head ITÂ )
* Uday Kalele (Vice President)

## People

Employees: **955 (1%)**

Median Tenure: **9.3 Yrs**

Institute Pedigree Score: **33.8%**

**Geography**

* India

  **(100%)**

**Top Institutes**

* Kurukshetra University

  **(17)**
* Punjab Technical University

  **(11)**
* Panjab University

  **(8)**
* Himachal Pradesh University

  **(8)**
* Chitkara University

  **(7)**

**Departments**

* Sales

  **(21%)**
* Operations

  **(12%)**
* Research

  **(11%)**
* Business Development

  **(10%)**
* Quality Assurance

  **(9%)**

**Top Skills**

* Pharmaceutics

  **(12%)**
* Good Manufacturing Practice (GMP)

  **(8%)**
* Standard Operating Procedure (SOP)

  **(5%)**
* Regulatory Affairs

  **(5%)**
* Pharmaceutical Sales

  **(4%)**

## Peers

- Sohan Healthcare
- Kopran Research Laboratories
- Surmount Laboratories
- Ajmera Pharmasure
- Precise Chemipharma
- Flagship Biotech
- Danopharm
- Ravian
- Jubilant Generics
- Relax Pharmaceuticals

## Facilities

- **Corporate facilities**
  - Chandigarh, Punjab, India

- **Marketing Office**
  - Mumbai, Maharashtra, India

- **R&D Office**
  - Navi Mumbai, Maharashtra, India



## Auditor Details

Not Available

## CARO Analysis

Not Available

## Deals Status

| Target Company | Investor | Divestor | Date | investmentType | Deal Size ($) (M) | Reported Deal size (INR) (M) | Stake (%) | Post Money Valuation (INR) (M) | Post Money Valuation USD ($) (M) | Source | Sources |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ind-Swift | Ind-Swift Laboratories Limited | N/A | 2025-08-08 | N/A | $8.58182M | INR708M | 100% | INR708M | $8.58M | https://in.marketscreener.com/news/ind-swift-laboratories-limited-completed-the-acquisition-of-ind-swift-limited-ce7c5edddc8bfe20 | [Link](https://in.marketscreener.com/news/ind-swift-laboratories-limited-completed-the-acquisition-of-ind-swift-limited-ce7c5edddc8bfe20) |

## Credit Status

| Instrument | Date Of Rating | Amount | Agency | Rating | Rating Status | Rating Grade |
|---|---|---|---|---|---|---|
| Others | 2015-06-26 | 1228.8 | ICRA | D | Suspended | Default |
| Non-fund-based financial facility/instrument | 2015-06-26 | 639.9 | ICRA | D | Suspended | Default |
| Cash Credit | 2015-06-26 | 2933.8 | ICRA | D | Suspended | Default |
| Term loans | 2015-06-26 | 2647.5 | ICRA | D | Suspended | Default |
| Others | 2014-02-18 | 1228.8 | ICRA | D | Reaffirmed | Default |
| Non-fund-based financial facility/instrument | 2014-02-18 | 639.9 | ICRA | D | Reaffirmed | Default |
| Cash Credit | 2014-02-18 | 2933.8 | ICRA | D | Reaffirmed | Default |
| Term loans | 2014-02-18 | 2647.5 | ICRA | D | Reaffirmed | Default |
| Non-fund-based financial facility/instrument | 2012-08-11 | 2300 | ICRA | D | Downgraded | Default |
| Cash Credit | 2012-08-11 | 3260 | ICRA | D | Downgraded | Default |
| Term loans | 2012-08-11 | 1550 | ICRA | D | Downgraded | Default |
| Fund based financial facility/instrument | 2012-08-11 | 340 | ICRA | D | Downgraded | Default |
| Term loans | 2012-06-29 | 1550 | ICRA | BB | Downgraded | Inadequate Safety |
| Fund based financial facility/instrument | 2012-06-29 | 3260 | ICRA | BB | Downgraded | Inadequate Safety |
| Non-fund-based financial facility/instrument | 2012-06-29 | 2300 | ICRA | A 4 | Downgraded | High Risk |
| Fund based financial facility/instrument | 2012-06-29 | 3.4 | ICRA | A 4 | Downgraded | High Risk |
| Term loans | 2011-07-19 | 1550 | ICRA | BBB | Reaffirmed & Enhanced | Moderate Safety |
| Fund based financial facility/instrument | 2011-07-19 | 3260 | ICRA | BBB | Reaffirmed & Enhanced | Moderate Safety |
| Non-fund-based financial facility/instrument | 2011-07-19 | 2300 | ICRA | A 3+ | Reaffirmed & Enhanced | Moderate Safety |
| Fund based financial facility/instrument | 2011-07-19 | 340 | ICRA | A 3+ | Reaffirmed & Reduced | Moderate Safety |
| Term loans | 2010-06-30 | 3046.7 | ICRA | LBBB | Reaffirmed & Enhanced | Moderate Safety |
| Non-fund-based financial facility/instrument | 2010-06-30 | 3183 | ICRA | A 3+ | Reaffirmed & Enhanced | Moderate Safety |
| Term loans | 2010-06-30 | 3183 | ICRA | A 3+ | Reaffirmed & Enhanced | Moderate Safety |
| Term loans | 2010-06-22 | 905.3 | ICRA | LBBB | Reaffirmed | Moderate Safety |
| Non-fund-based financial facility/instrument | 2010-06-22 | 682.2 | ICRA | A 3+ | Reaffirmed | Moderate Safety |
| Term loans | 2010-06-22 | 924 | ICRA | A 3+ | Reaffirmed | Moderate Safety |
| Term loans | 2009-05-25 | 905.3 | ICRA | LBBB | Downgraded | Moderate Safety |
| Non-fund-based financial facility/instrument | 2009-05-25 | 924 | ICRA | A 3+ | Downgraded | Moderate Safety |
| Term loans | 2009-05-25 | 682.2 | ICRA | A 3+ | Downgraded | Moderate Safety |
| Non-fund-based financial facility/instrument | 2008-03-14 | 924 | ICRA | A 2 | Initial Rating | High Safety |

## Financials Status

## Financials Status

### Income Statement
- Revenue From Operations | 2014: None | 2015: None | 2016: 3077.48335 | 2017: 2672.02709 | 2018: 2705.70533 | 2019: None | 2020: None | 2021: None | 2022: 4017.6 | 2023: 4109.584 | 2024: 5022.477 | 2025: None
   - Revenue From Sale of Products | 2014: None | 2015: None | 2016: 3054.87279 | 2017: 2653.13421 | 2018: 2662.3908 | 2019: None | 2020: None | 2021: None | 2022: 3953.4 | 2023: 3988.915 | 2024: 4925.293 | 2025: None
      - Total Export Turnover Goods, Gross | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
         - Export Sale Traded Goods | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
         - Export Sale Manufactured Goods | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
      - Total Domestic Turnover Goods, Gross | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
         - Domestic Sale Traded Goods | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
         - Domestic Sale Manufactured Goods | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Revenue From Sale of Services | 2014: None | 2015: None | 2016: 22.61056 | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: 64.2 | 2023: None | 2024: None | 2025: None
      - Export Revenue Services | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
      - Domestic Revenue Services | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Material Costs | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Cost of material consumed | 2014: None | 2015: None | 2016: 2190.41082 | 2017: 1037.05582 | 2018: 1253.47821 | 2019: None | 2020: None | 2021: None | 2022: 1922.8 | 2023: 1949.74 | 2024: 2064.967 | 2025: None
   - Purchases of stock-in-trade | 2014: None | 2015: None | 2016: None | 2017: 662.53582 | 2018: 368.92236 | 2019: None | 2020: None | 2021: None | 2022: 201.5 | 2023: 384.965 | 2024: 448.334 | 2025: None
   - Changes in inventories of FG, WIP and SIT | 2014: None | 2015: None | 2016: 14.36867 | 2017: -39.30236 | 2018: -80.85057 | 2019: None | 2020: None | 2021: None | 2022: -14.1 | 2023: -154.294 | 2024: 298.463 | 2025: None
- Material Margin | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Employee Benefit Expense | 2014: None | 2015: None | 2016: 403.69776 | 2017: 423.86944 | 2018: 482.69658 | 2019: None | 2020: None | 2021: None | 2022: 631.4 | 2023: 691.467 | 2024: 783.172 | 2025: None
- Other Total Expenses | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Operating EBITDA | 2014: None | 2015: None | 2016: -1569.5101599999994 | 2017: -654.0105599999997 | 2018: 62.95632000000023 | 2019: None | 2020: None | 2021: None | 2022: 494.20000000000016 | 2023: 420.3329999999999 | 2024: 485.1360000000003 | 2025: None
- Total depreciation, depletion and amortisation expense | 2014: None | 2015: None | 2016: 363.51463 | 2017: 357.32239 | 2018: 346.31275 | 2019: None | 2020: None | 2021: None | 2022: 320.7 | 2023: 286.678 | 2024: 271.071 | 2025: None
- EBIT | 2014: None | 2015: None | 2016: -1807.9749799999995 | 2017: -874.5297099999998 | 2018: -181.72356999999977 | 2019: None | 2020: None | 2021: None | 2022: 243.9000000000002 | 2023: 252.1959999999999 | 2024: 793.9950000000002 | 2025: None
- Finance Cost | 2014: None | 2015: None | 2016: 189.67886 | 2017: 163.15884 | 2018: 70.53256 | 2019: None | 2020: None | 2021: None | 2022: 571.6 | 2023: 597.616 | 2024: 629.36 | 2025: None
- Other Income | 2014: None | 2015: None | 2016: 125.04981 | 2017: 136.80324 | 2018: 101.63286 | 2019: None | 2020: None | 2021: None | 2022: 70.4 | 2023: 118.541 | 2024: 579.93 | 2025: None
- PBT | 2014: None | 2015: None | 2016: -1997.6538399999995 | 2017: -1037.6885499999999 | 2018: -252.25612999999976 | 2019: None | 2020: None | 2021: None | 2022: -327.6999999999998 | 2023: -345.4200000000001 | 2024: 164.63500000000022 | 2025: None
   - Tax expense | 2014: None | 2015: None | 2016: 1.74624 | 2017: 8.93532 | 2018: 7.50727 | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: 22.322 | 2025: None
- PAT | 2014: None | 2015: None | 2016: -1999.4000799999994 | 2017: -1046.62387 | 2018: -259.76339999999976 | 2019: None | 2020: None | 2021: None | 2022: -327.6999999999998 | 2023: -345.4200000000001 | 2024: 142.31300000000022 | 2025: None

### Balance Sheet
- Equities | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Share Capital | 2014: None | 2015: None | 2016: 242.69388 | 2017: 250.3293 | 2018: 250.3293 | 2019: None | 2020: None | 2021: None | 2022: 250.3 | 2023: 108.3293 | 2024: 108.3293 | 2025: None
   - Reserves & Surplus | 2014: None | 2015: None | 2016: -2763.84715 | 2017: -6405.35514 | 2018: -6882.13788 | 2019: None | 2020: None | 2021: None | 2022: -7311.5 | 2023: -7155.317 | 2024: -7016.581 | 2025: None
- Borrowings | 2014: None | 2015: None | 2016: 10429.0586 | 2017: 10482.91848 | 2018: 10410.38307 | 2019: None | 2020: None | 2021: None | 2022: 9708.2 | 2023: 9926.159 | 2024: 10139.957 | 2025: None
   - Long term Borrowings | 2014: None | 2015: None | 2016: 6716.52406 | 2017: 6647.69878 | 2018: 6669.97856 | 2019: None | 2020: None | 2021: None | 2022: 6053 | 2023: 4031.11 | 2024: 10095.035 | 2025: None
   - Short Term Borrowings | 2014: None | 2015: None | 2016: 3712.53454 | 2017: 3835.2197 | 2018: 3740.40451 | 2019: None | 2020: None | 2021: None | 2022: 3655.2 | 2023: 5895.049 | 2024: 44.922 | 2025: None
- Long Term Provisions | 2014: None | 2015: None | 2016: 20.40159 | 2017: 26.37504 | 2018: 56.60531 | 2019: None | 2020: None | 2021: None | 2022: 75.6 | 2023: 76.72 | 2024: 86.598 | 2025: None
- Other Long Term Liabilities | 2014: None | 2015: None | 2016: 56.38615 | 2017: 48.08586 | 2018: 70.35635 | 2019: None | 2020: None | 2021: None | 2022: 70 | 2023: 67.961 | 2024: 67.663 | 2025: None
- Deferred tax liabilities (net) | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Sources of Funds | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Non-Current Assets | 2014: None | 2015: None | 2016: 4431.82879 | 2017: 4581.33355 | 2018: 4286.44623 | 2019: None | 2020: None | 2021: None | 2022: 3893.1 | 2023: 3758.264 | 2024: 3126.784 | 2025: None
   - Total fixed assets | 2014: None | 2015: None | 2016: 3778.11551 | 2017: 3445.29793 | 2018: 3106.81255 | 2019: None | 2020: None | 2021: None | 2022: 2445.1 | 2023: 2461.924 | 2024: 2352.918 | 2025: None
      - Tangible assets | 2014: None | 2015: None | 2016: 3442.93361 | 2017: 3146.88587 | 2018: 2866.83731 | 2019: None | 2020: None | 2021: None | 2022: 2251.2 | 2023: 2045.392 | 2024: 1735.252 | 2025: None
         - Gross fixed assets | 2014: None | 2015: None | 2016: 0 | 2017: 0 | 2018: 0 | 2019: None | 2020: None | 2021: None | 2022: 0 | 2023: 0 | 2024: 0 | 2025: None
         - Accumulated depreciation and impairment | 2014: None | 2015: None | 2016: 0 | 2017: 0 | 2018: 0 | 2019: None | 2020: None | 2021: None | 2022: 0 | 2023: 0 | 2024: 0 | 2025: None
      - Intangible assets | 2014: None | 2015: None | 2016: 298.50748 | 2017: 276.23707 | 2018: 239.97523 | 2019: None | 2020: None | 2021: None | 2022: 103.9 | 2023: 119.249 | 2024: 105.217 | 2025: None
      - CWIP | 2014: None | 2015: None | 2016: 22.17498 | 2017: 22.17498 | 2018: None | 2019: None | 2020: None | 2021: None | 2022: 90 | 2023: 297.283 | 2024: 512.449 | 2025: None
   - Non Current Investments | 2014: None | 2015: None | 2016: 391.69137 | 2017: 394.08885 | 2018: 458.98674 | 2019: None | 2020: None | 2021: None | 2022: 643.5 | 2023: 537.326 | 2024: 12.607 | 2025: None
   - Deferred tax assets (net) | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Long Term Loans and Advances | 2014: None | 2015: None | 2016: 163.12212 | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: 804.5 | 2023: None | 2024: None | 2025: None
   - Other Non-Current Assets | 2014: None | 2015: None | 2016: 98.89977 | 2017: 741.94675 | 2018: 720.64694 | 2019: None | 2020: None | 2021: None | 2022: None | 2023: 759.014 | 2024: 761.259 | 2025: None
- Adj Current Assets | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Current Investments | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Inventories | 2014: None | 2015: None | 2016: 909.40601 | 2017: 390.59782 | 2018: 454.37301 | 2019: None | 2020: None | 2021: None | 2022: 695.8 | 2023: 893.482 | 2024: 640.915 | 2025: None
   - Trade Receivables | 2014: None | 2015: None | 2016: 3803.3026 | 2017: 1084.80978 | 2018: 835.04626 | 2019: None | 2020: None | 2021: None | 2022: 1476.7 | 2023: 1045.839 | 2024: 1521.425 | 2025: None
   - Short Term Loans and Advances | 2014: None | 2015: None | 2016: 869.10848 | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: 660.5 | 2023: None | 2024: None | 2025: None
   - Other Current Assets | 2014: None | 2015: None | 2016: 360.74023 | 2017: 497.82459 | 2018: 534.92827 | 2019: None | 2020: None | 2021: None | 2022: None | 2023: 661.244 | 2024: 624.221 | 2025: None
- Adj Current Liabilities | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Trade Payables | 2014: None | 2015: None | 2016: 1753.81515 | 2017: 1617.59962 | 2018: 1663.01194 | 2019: None | 2020: None | 2021: None | 2022: 2039.1 | 2023: 2347.289 | 2024: 2018.91 | 2025: None
   - Short Term Provisions | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: 582.1 | 2023: 15.996 | 2024: 18.254 | 2025: None
   - Other Current Liabilities | 2014: None | 2015: None | 2016: 742.96302 | 2017: 625.6639 | 2018: 578.99775 | 2019: None | 2020: None | 2021: None | 2022: 1474.1 | 2023: 1104.97 | 2024: 1121.583 | 2025: None
- Cash & Bank Balances | 2014: None | 2015: None | 2016: 173.89513 | 2017: 91.05133 | 2018: 36.75207 | 2019: None | 2020: None | 2021: None | 2022: 161.8 | 2023: 133.278 | 2024: 631.368 | 2025: None
- Use of Funds | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None

### Cash Flow
- Net cash flow from operating activities | 2014: None | 2015: None | 2016: -3042.97384 | 2017: -17.20817 | 2018: 71.66022 | 2019: None | 2020: None | 2021: None | 2022: 502 | 2023: 730.459 | 2024: 152.828 | 2025: None
   - Net profit before tax and extra ordinary income | 2014: None | 2015: None | 2016: -1997.65384 | 2017: -1037.68854 | 2018: -252.25613 | 2019: None | 2020: None | 2021: None | 2022: -203.4 | 2023: -345.42 | 2024: 164.635 | 2025: None
   - Adjustments for non-cash and non-operating expenses and income | 2014: None | 2015: None | 2016: 314.571 | 2017: 3616.532 | 2018: 605.431 | 2019: None | 2020: None | 2021: None | 2022: 779.3 | 2023: 470.092 | 2024: -11.807 | 2025: None
   - Cash Inflow/Outflow due to working capital changes | 2014: None | 2015: None | 2016: -1576.705 | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: -69.7 | 2023: None | 2024: None | 2025: None
   - Cash flow generated from operations | 2014: None | 2015: None | 2016: -3259.78784 | 2017: -17.20817 | 2018: 71.66022 | 2019: None | 2020: None | 2021: None | 2022: 506.2 | 2023: 730.459 | 2024: 152.828 | 2025: None
   - Cash inflow or (outflow) from extraordinary items | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Cash (outflow) due to miscellaneous expenditure | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Net cash flow from investment activities | 2014: None | 2015: None | 2016: 43.436 | 2017: 41.439 | 2018: -64.242 | 2019: None | 2020: None | 2021: None | 2022: -184.2 | 2023: -293.45 | 2024: 766.072 | 2025: None
   - Purchase of fixed Assets | 2014: None | 2015: None | 2016: 41.773 | 2017: 39.949 | 2018: -98.568 | 2019: None | 2020: None | 2021: None | 2022: -195.8 | 2023: -308.298 | 2024: -284.931 | 2025: None
   - Sale of Fixed Assets | 2014: None | 2015: None | 2016: None | 2017: None | 2018: 32.973 | 2019: None | 2020: None | 2021: None | 2022: 1 | 2023: None | 2024: None | 2025: None
   - Purchase of Investments | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Sale of Investments | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Interest Received | 2014: None | 2015: None | 2016: 1.663 | 2017: 1.49 | 2018: 1.353 | 2019: None | 2020: None | 2021: None | 2022: 10.6 | 2023: 7.732 | 2024: 19.425 | 2025: None
   - Dividend Received | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Net cash flow from financing activities | 2014: None | 2015: None | 2016: 13402.086 | 2017: -107.07462 | 2018: -61.71749 | 2019: None | 2020: None | 2021: None | 2022: -445.9 | 2023: -465.556 | 2024: -420.81 | 2025: None
   - Proceeds from Share Issue / Share Warrants | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Redemption or Buyback of Capital | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - Proceeds from Borrowings | 2014: None | 2015: None | 2016: 13618.9 | 2017: 70.88 | 2018: 65.59 | 2019: None | 2020: None | 2021: None | 2022: 880.5 | 2023: None | 2024: None | 2025: None
   - Repayment of Borrowings | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: -741.9 | 2023: -347.496 | 2024: -7037.28 | 2025: None
   - Interest Paid | 2014: None | 2015: None | 2016: -216.814 | 2017: -152.63262 | 2018: -11.45249 | 2019: None | 2020: None | 2021: None | 2022: -582.7 | 2023: -636.947 | 2024: -634.31 | 2025: None
   - Dividend Paid | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - cf_net_change_in_cash_ncash_eq | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - cf_cash_ncash_eq_beg | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
   - cf_cash_ncash_eq_end | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Net change in cash and cash equivalents | 2014: None | 2015: None | 2016: 10402.54815 | 2017: -82.84379 | 2018: -54.29926 | 2019: None | 2020: None | 2021: None | 2022: -128.1 | 2023: -28.547 | 2024: 498.09 | 2025: None
- Cash and cash equivalents as at the beginning of the year | 2014: None | 2015: None | 2016: -10228.65301 | 2017: 173.89513 | 2018: 91.05133 | 2019: None | 2020: None | 2021: None | 2022: 289.9 | 2023: 161.825 | 2024: 133.278 | 2025: None
- Cash and cash equivalents as at the end of the year | 2014: None | 2015: None | 2016: 173.89513 | 2017: 91.05133 | 2018: 36.75207 | 2019: None | 2020: None | 2021: None | 2022: 161.8 | 2023: 133.278 | 2024: 631.368 | 2025: None

### Ratios
- Revenue From Operations | 2014: None | 2015: None | 2016: 3077.48335 | 2017: 2672.02709 | 2018: 2705.70533 | 2019: None | 2020: None | 2021: None | 2022: 4017.6 | 2023: 4109.584 | 2024: 5022.477 | 2025: None
- Material Margin | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- Operating EBITDA | 2014: None | 2015: None | 2016: -1569.5101599999994 | 2017: -654.0105599999997 | 2018: 62.95632000000023 | 2019: None | 2020: None | 2021: None | 2022: 494.20000000000016 | 2023: 420.3329999999999 | 2024: 485.1360000000003 | 2025: None
- PAT Margin | 2014: None | 2015: None | 2016: -62.431830487488725 | 2017: -37.26191130504522 | 2018: -9.253014118498431 | 2019: None | 2020: None | 2021: None | 2022: -8.016144814090016 | 2023: -8.16957871396896 | 2024: 2.5402117339921966 | 2025: None
- roic | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- RoCE | 2014: None | 2015: None | 2016: -41.6683127183955 | 2017: -154.20163945069334 | 2018: -110.04769225039506 | 2019: None | 2020: None | 2021: None | 2022: -28.274982610711813 | 2023: -8.78365364689361 | 2024: 0.7369459534777795 | 2025: None
- ROE | 2014: None | 2015: None | 2016: None | 2017: 24.12637767686656 | 2018: 4.062982149728968 | 2019: None | 2020: None | 2021: None | 2022: 4.786384206004782 | 2023: 4.89673099543466 | 2024: 5.427433060142918 | 2025: None
- Asset Turnover | 2014: None | 2015: None | 2016: None | 2017: 0.3267240834886057 | 2018: 0.4388810199895727 | 2019: None | 2020: None | 2021: None | 2022: 0.6272129157745686 | 2023: 0.6320063958113027 | 2024: 0.8594744730693529 | 2025: None
- networking capital | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- fixed asset turnover | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- core net work cap | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- inventory_days | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- receivable_days | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None
- payable_days | 2014: None | 2015: None | 2016: None | 2017: None | 2018: None | 2019: None | 2020: None | 2021: None | 2022: None | 2023: None | 2024: None | 2025: None

